

File No. 250743

Committee Item No. 6

Board Item No. 44

COMMITTEE/BOARD OF SUPERVISORS

AGENDA PACKET CONTENTS LIST

Committee: Budget and Finance Committee Date July 23, 2025

Board of Supervisors Meeting Date July 29, 2025

Cmte Board

- | | | |
|-------------------------------------|-------------------------------------|--|
| ☐ | ☐ | Motion |
| ☒ | ☒ | Resolution |
| ☐ | ☐ | Ordinance |
| ☐ | ☐ | Legislative Digest |
| ☐ | ☐ | Budget and Legislative Analyst Report |
| ☐ | ☐ | Youth Commission Report |
| ☐ | ☐ | Introduction Form |
| ☒ | ☒ | Department/Agency Cover Letter and/or Report |
| ☐ | ☐ | MOU |
| ☒ | ☒ | Grant Information Form |
| ☒ | ☒ | Grant Budget |
| | | • Grant Budget Justification |
| | | • Grant All Years Budgets |
| ☐ | ☐ | Subcontract Budget |
| ☐ | ☐ | Contract/Agreement |
| ☐ | ☐ | Form 126 – Ethics Commission |
| ☒ | ☒ | Award Letter |
| ☒ | ☒ | Application |
| ☐ | ☐ | Public Correspondence |

OTHER (Use back side if additional space is needed)

- | | | |
|-------------------------------------|-------------------------------------|--|
| ☒ | ☒ | Grant Agreement 4/1/2024 |
| ☒ | ☒ | Modification No. 1 11/14/2024 |
| ☒ | ☒ | Modification No. 2 4/17/2025 |
| ☒ | ☒ | DPH Statement on Retroactivity 7/17/2025 |
| ☒ | ☒ | DPH Presentation 7/23/2025 |
| ☐ | ☐ | |
| ☐ | ☐ | |
| ☐ | ☐ | |
| ☐ | ☐ | |
| ☐ | ☐ | |
| ☐ | ☐ | |
| ☐ | ☐ | |

Completed by: Brent Jalipa Date July 17, 2025

Completed by: Brent Jalipa Date July 24, 2025

1 [Accept and Expend Grant - Retroactive - National Institutes of Health - Family Health
2 International - HIV Prevention Trials Network - \$108,968]

3 **Resolution retroactively authorizing the Department of Public Health to accept and**
4 **expend a grant from the National Institutes of Health through the Family Health**
5 **International for participation in a program, entitled “HIV Prevention Trials Network**
6 **(HPTN),” in the amount of \$108,968 for the period of April 1, 2024, through November**
7 **30, 2025.**

8
9 WHEREAS, The National Institutes of Health (NIH), through the Family Health
10 International (FHI 360) as a pass-through entity, has agreed to fund the Department of Public
11 Health (DPH) in the amount of \$108,968 for participation in a program, entitled “HIV
12 Prevention Trials Network (HPTN),” for the period of April 1, 2024, through November 30,
13 2025; and

14 WHEREAS, DPH provides scientific guidance in developing and testing interventions
15 designed to prevent the transmission of human immunodeficiency virus (HIV); and

16 WHEREAS, The main purpose of this study is to adapt and test a suite of health tools
17 to increase HIV pre-exposure prophylaxis (PrEP) uptake and adherence among young Latino
18 gay, bisexual, and other cis-gender men who have sex with men (MSM) and evaluate the
19 uptake, adherence, and acceptability of doxycycline for sexually transmitted infection (STI)
20 post-exposure prophylaxis (DoxyPEP); and

21 WHEREAS, The grant does not require an Annual Salary Ordinance Amendment; and

22 WHEREAS, A request for retroactive approval is being sought because DPH received
23 the original grant agreement on June 12, 2024, for a project start date of April 1, 2024, in the
24 amount of \$48,915, then received an increase in grant funds on November 12, 2024, in the
25 amount of \$36,686 for a total amount of \$85,601, for a project start date of April 1, 2024, and

1 received approval for another increase in grant funds from the NIH on April 17, 2025, in the
2 amount of \$23,367 for a total amount of \$108,968, for a project start date of April 1, 2024; and

3 WHEREAS, The grant budget includes a provision for indirect costs in the amount of
4 \$19,987; now, therefore, be it

5 RESOLVED, That DPH is hereby authorized to retroactively accept and expend a grant
6 in the amount of \$108,968 from the NIH through FHI 360, to participate in a program, entitled,
7 "HIV Prevention Trials Network (HPTN)," for the period of April 1, 2024, through November
8 30, 2025; and, be it

9 FURTHER RESOLVED, That DPH is hereby authorized to retroactively accept and
10 expend the grant funds pursuant to Administrative Code, Section 10.170-1; and, be it

11 FURTHER RESOLVED, That the Director of Health is authorized to enter into the
12 Grant Agreement on behalf of the City; and, be it

13 FURTHER RESOLVED, That within thirty (30) days of the Grant Agreement being fully
14 executed by all parties, the Director of Health shall provide a copy to the Clerk of the Board of
15 Supervisors for inclusion in the official file.

1 Recommended: Approved: _____/s/_____
2 Mayor
3 _____/s/_____
4 Daniel Tsai Approved: _____/s/_____
5 Director of Health Controller
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25

File Number: 250743
(Provided by Clerk of Board of Supervisors)

Grant Resolution Information Form
(Effective July 2011)

Purpose: Accompanies proposed Board of Supervisors resolutions authorizing a Department to accept and expend grant funds.

The following describes the grant referred to in the accompanying resolution:

1. Grant Title: **HIV Prevention Trials Network (HPTN)**
2. Department: **Department of Public Health
Population Health Division**
3. Contact Person: **Susan Buchbinder** Telephone: **415-476-2300**
4. Grant Approval Status (check one):

☒ Approved by funding agency

☐ Not yet approved

5. Amount of Grant Funding Approved or Applied for: **\$108,968**
(Year 1 April 01, 2024 – November 30, 2025: \$48,915
Year 2 December 01, 2024 – November 30, 2025: \$36,686
Year 2 December 01, 2024 – November 30, 2025: \$23,367)

- 6a. Matching Funds Required: **\$0**
- b. Source(s) of matching funds (if applicable): **N.A.**

- 7a. Grant Source Agency: **National Institutes of Health (NIH)**
- b. Grant Pass-Through Agency (if applicable): **Family Health International ("FHI 360")**

8. Proposed Grant Project Summary:

This funding allows for Department of Public Health (DPH) to provide scientific guidance in developing and testing interventions designed to prevent the transmission of human immunodeficiency virus (HIV). The main purpose of this study is to adapt and test a suite of mHealth tools to increase HIV pre-exposure prophylaxis (PrEP) uptake and adherence among young Latino gay, bisexual, and other cis-gender men who have sex with men (MSM) and evaluate the uptake, adherence, and acceptability of doxycycline for sexually transmitted infection (STI) post-exposure prophylaxis (DoxyPEP).

9. Grant Project Schedule, as allowed in approval documents, or as proposed:

Start-Date: **04/01/2024**

End-Date: **11/30/2025**

- 10a. Amount budgeted for contractual services: **\$0**

- b. Will contractual services be put out to bid? **N.A.**
- c. If so, will contract services help to further the goals of the Department's Local Business Enterprise (LBE) requirements? **N.A.**
- d. Is this likely to be a one-time or ongoing request for contracting out? **N.A.**

11a. Does the budget include indirect costs? ☒ Yes ☐ No

b1. If yes, how much? **\$19,987**
b2. How was the amount calculated? **22.46% of Total Personnel Cost**

c1. If no, why are indirect costs not included? **N.A.**
☐ Not allowed by granting agency ☐ To maximize use of grant funds on direct services
☐ Other (please explain):

c2. If no indirect costs are included, what would have been the indirect costs? **N.A.**

12. Any other significant grant requirements or comments:

We respectfully request for approval to accept and expend these funds retroactive to April 1, 2024. The Department received Yr1 award of \$48,915 on June 12, 2024 and Yr2 award of \$36,686 on November 12, 2024 and \$23,367 on April 17, 2025, for a total of \$108,968 for the period of April 1, 2024, to November 30, 2025. The AL # for this grant is 93.855.

The grant does not require an ASO amendment, does not create net new positions, and partially reimburses the department for the existing positions:

No.	Class	Job Title	FTE	Start Date	End Date
1	2233	Supervising Physician Specialist	0.10	04/01/2024	11/30/2025
2	2232	Sr Physician Specialist	0.05	04/01/2024	11/30/2025
3	2232	Sr Physician Specialist	0.05	04/01/2024	11/30/2025

Project Description: HIV Prevention Trials Network (HPTN)
Proposal ID: CTR00004859
Fund ID: 11580
Dept. ID: 162646
Project ID: 10042554
Authority ID: 10001
Activity ID: 0001

****Disability Access Checklist** (Department must forward a copy of all completed Grant Information Forms to the Mayor's Office of Disability)**

13. This Grant is intended for activities at (check all that apply):

- | | | |
|--|---|--|
| ☒ Existing Site(s) | ☐ Existing Structure(s) | ☐ Existing Program(s) or Service(s) |
| ☐ Rehabilitated Site(s) | ☐ Rehabilitated Structure(s) | ☐ New Program(s) or Service(s) |
| ☐ New Site(s) | ☐ New Structure(s) | |

14. The Departmental ADA Coordinator or the Mayor's Office on Disability have reviewed the proposal and concluded that the project as proposed will be in compliance with the Americans with Disabilities Act and all other Federal, State and local disability rights laws and regulations and will allow the full inclusion of persons with disabilities. These requirements include, but are not limited to:

1. Having staff trained in how to provide reasonable modifications in policies, practices and procedures;
2. Having auxiliary aids and services available in a timely manner in order to ensure communication access;
3. Ensuring that any service areas and related facilities open to the public are architecturally accessible and have been inspected and approved by the DPW Access Compliance Officer or the Mayor's Office on Disability Compliance Officers.

If such access would be technically infeasible, this is described in the comments section below:

Comments:

Departmental ADA Coordinator or Mayor's Office of Disability Reviewer:

Toni Rucker, PhD

(Name)

DPH ADA Coordinator

(Title)

Date Reviewed: 6/6/2025 | 10:31 AM PDT

DocuSigned by:
Toni Rucker
(Signature Required)

Department Head or Designee Approval of Grant Information Form:

Daniel Tsai

(Name)

Director of Health

(Title)

Date Reviewed: 6/27/2025 | 10:51 AM PDT

Signed by:
Jenny Louie for Daniel Tsai
40CFE25DD8B4464...

Grant Increases:



**National Institutes of Health - Fred Hutchinson
Cancer Center - Statistical Methods for Advancing
HIV Prevention**

**National Institutes of Health - Family Health
International - HIV Prevention Trials Network**

BOS Budget & Finance Committee

Dr. Susan Buchbinder, Director, Bridge HIV, Population Health Division

July 23, 2025

SAN FRANCISCO DEPARTMENT OF PUBLIC HEALTH

Overview of File 250725



National Institutes of Health - Fred Hutchinson Cancer Center - Statistical Methods for Advancing HIV Prevention

- **Amount:** \$105,832
- **Timeline:** March 1, 2023 – February 28, 2026
- **Grantor:** National Institutes of Health through Fred Hutchinson Cancer Center
- **Grant Summary:** Supports DPH's participation in the Statistical Methods for Advancing HIV Prevention Program
 - Provide scientific guidance in developing statistical methods for testing the safety and efficacy of vaccine interventions designed to prevent the transmission of human immunodeficiency virus (HIV)

Retroactivity



We are seeking **retroactive authorization** to accept this grant increase.

- The initial project period for this grant began on March 1, 2023.
- DPH received several grant increases for this grant.
- SFDPH received notice of the most recent grant increase on May 12, 2025, for a project start date of March 1, 2025.
- DPH brought this item to the BOS after going through the fiscal approvals process, including Controller's Office review and approval.

Overview of File 250743



National Institutes of Health - Family Health International - HIV Prevention Trials Network:

- **Amount:** \$108,968
- **Timeline:** April 1, 2024 – November 30, 2025
- **Funder:** National Institutes of Health, through Family Health International
- **Grant Summary:** support DPH's participation in the HIV Prevention Trials Network (HPTN)
 - Adapt and test a suite of health tools to increase HIV pre-exposure prophylaxis (PrEP) and STI post-exposure prophylaxis (DoxyPEP) uptake and adherence among young Latino gay, bisexual, and other cis-gender MSM

Retroactivity



We are seeking **retroactive authorization** to accept this grant increase.

- The initial project period for this grant began on April 1, 2024.
- DPH received several grant increases for this grant.
- SFDPH received notice of the most recent grant increase on April 17, 2025, for a project start date of March 1, 2025.
- DPH brought this item to the BOS after going through the fiscal approvals process, including Controller's Office review and approval.



Conclusion

DPH respectfully requests retroactive approval of these items. Thank you!

DETAILED BUDGET FOR NEXT BUDGET PERIOD - DIRECT COSTS ONLY		FROM	THROUGH	GRANT NUMBER			
		4/1/2024	11/30/24				
List PERSONNEL (Applicant organization only)							
Use Cal, Acad, or Summer to Enter Months Devoted to Project							
Enter Dollar Amounts Requested (omit cents) for Salary Requested and Fringe Benefits							
NAME	ROLE ON PROJECT	Cal. Mnths	Acad. Mnths	Summ. Mnths	SALARY REQUESTED	FRINGE BENEFITS	TOTAL
S. Buchbinder	Co-Pi	0.100	8		14,793	5,178	19,971
A. Liu	Co-Pi	0.05	8		7,397	2,589	9,986
H. Scott	Co-Pi	0.05	8		7,397	2,589	9,986
					29,587	10,356	39,943
CONSULTANT COSTS							
EQUIPMENT							
							0
SUPPLIES							
Clinical/Lab Supplies							
							0
TRAVEL							
Domestic Conference for 2 Investigators							
PATIENT CARE COSTS		INPATIENT					
		OUTPATIENT					
ALTERATIONS AND RENOVATIONS							
OTHER EXPENSES							
							0
SUBTOTAL DIRECT COST FOR NEXT BUDGET PERIOD							39,943
CONSORTIUM/CONTRACTUAL COSTS		DIRECT COSTS					0
CONSORTIUM/CONTRACTUAL COSTS		SFDPH Indirects 22.462% of Direct Cost					8,972
TOTAL DIRECT COSTS FOR NEXT BUDGET PERIOD							48,915



ATTACHMENT B
BUDGET



Subawardee:	City and County of San Francisco	Start Date:	4/1/2024
PO#	PO24002400	End Date:	11/30/2025
Subaward title:	HPTN 113 Leadership (Buchbinder)		

	Previous Funding Period Obligation	Current Funding Period Obligation	Total Obligation	Total Life of Project
	Apr 1 2024 - Nov 30 2024	Dec 1 2024 - Nov 30 2024	Apr 1 2024 - Nov 30 2025	Apr 1 2024 - Nov 30 2025
	Amount	Amount	Amount	Amount
	USD	USD	USD	USD
1. SALARIES	29,587	22,190	51,777	51,777
2. FRINGE BENEFITS	10,356	7,767	18,123	18,123
3. CONSULTANTS	-		-	-
4. EQUIPMENT	-		-	-
5. TRAVEL/TRANSPORTATION	-		-	-
6. SUBAWARDS	-		-	-
7. OTHER DIRECT COSTS	-		-	-
8. INDIRECT COST/G&A	8,972	6,729	15,701	15,701
TOTAL PROJECT COSTS	48,915	36,686	85,601	85,601



ATTACHMENT B
BUDGET



Subawardee:	City and County of San Francisco	Start Date:	4/1/2024
PO#	PO24002400	End Date:	11/30/2025
Subaward title:	HPTN 113 Leadership (Buchbinder)		

	Previous Funding Period Obligation	Current Funding Period Obligation	Additional Funding Current Period	Deobligation	Total Obligation	Total Life of Project
	Apr 1 2024 - Nov 30 2024	Dec 1 2024 - Nov 30 2025	Dec 1 2024 - Nov 30 2025	Apr 1 2024 - Nov 30 2025	Apr 1 2024 - Nov 30 2025	Apr 1 2024 - Nov 30 2025
	Amount	Amount	Amount	Amount	Amount	Amount
	USD	USD	USD	USD	USD	USD
1. SALARIES	29,587	22,190	22,190	(5,434)	68,533	68,533
2. FRINGE BENEFITS	10,356	7,767	7,101	(4,776)	20,448	20,448
3. CONSULTANTS	-				-	-
4. EQUIPMENT	-				-	-
5. TRAVEL/TRANSPORTATION	-				-	-
6. SUBAWARDS	-				-	-
7. OTHER DIRECT COSTS	-				-	-
8. INDIRECT COST/G&A	8,972	6,729	6,579	(2,293)	19,987	19,987
TOTAL PROJECT COSTS	48,915	36,686	35,870	(12,503)	108,968	108,968



SAN FRANCISCO DEPARTMENT OF PUBLIC HEALTH
Population Health Division
HIV Prevention Trials Network (HPTN)
April 1, 2024 - November 30, 2025

		Year 1 Project: 10042259 4/1/24-11/30/24	Year 2 Project: 10042554 12/1/24 - 11/30/25		Total Amount	Unspent for YR1 Reduce
	Personnel -				-	
	Supervising Physician Specialist	14,793	11,095	11,095	36,983	(2,712)
	Supervising Physician Specialist	7,397	5,548	5,547	18,492	(1,361)
	Supervising Physician Specialist	7,397	5,548	5,547	18,492	(1,361)
					-	
	Fringe benefits	10,356	7,767	7,101	25,224	(4,776)
					-	
	Travel				-	
					-	
	Contractual				-	
					-	
					-	
	Indirect Costs	8,972	6,729	6,579	22,280	(2,293)
Total		48,915	36,686	35,870	121,471	(12,503)

From: Wong, Greg (DPH)
Sent: Wednesday, July 9, 2025 1:31 PM
Subject: FW: For Signature HPTN 113 PO24002400 SFDPH City and County SF - Modification #1

Please find below the email from the grantor. Initially, we had reached out to the grantor for an award letter from the National Institutes of Health to their organization but we were advised that they do not forward prime award information with external parties. They have forwarded an email below that confirms the award number [5UM1AI068619-19](#) which shows them as the recipient of the award from NIH, please find below. Please let me know if more information is needed. I apologize for the inconvenience.

<https://reporter.nih.gov/search/8tKqXvcg7E2Dlhwqsyq1hA/project-details/10991009>

NIH RePORT > RePORTER

Search Results > **Project Details**

[Back to Search Results](#)

HIV Prevention Trials Network Leadership and Operations Center

Description

Details

Sub-Projects

Publications

Patents

Outcomes

Clinical Studies

News and More

History

Similar Projects

Project Number
5UM1AI068619-19

Contact PI/Project Leader
COHEN, MYRON SCOTT
Other PIs

Awardee Organization
FAMILY HEALTH INTERNATIONAL

Description

Abstract Text
PROJECT SUMMARY The overarching goal of the HIV Prevention Trials Network (HPTN) is to identify acceptable, feasible, safe, effective and scalable interventions for HIV prevention that address the needs of populations at risk in the U.S. and around the world. The HPTN will address this goal by identifying: 1) new biomedical products and tools for HIV prevention that have unique characteristics, such as longer duration of action, new targets for inhibition of HIV replication, or as multipurpose prevention technologies (MPTs); and (2) integrated strategies that optimize use of proven efficacious prevention interventions and new tools tailored to specific populations at risk to achieve maximal public health impact. These interventions will be evaluated in priority populations for HIV prevention including women in sub-Saharan Africa, young men and women at risk, men who have sex with men (MSM), transgender women (TGW) who have sex with men, female sex workers (FSW) and persons who inject drugs (PWID). The specific aims of this research will be 1) To design and conduct studies of long-acting antiretroviral (ARV) agents and delivery systems for pre-exposure prophylaxis (PrEP); 2) To design and conduct studies to evaluate MPTs that concurrently prevent HIV and pregnancy, sexually transmitted infections (STIs) or opioid dependence; 3) To design and conduct studies in collaboration with the HIV Vaccine Trials Network to evaluate broadly neutralizing antibodies (bnAbs), alone and in combination, for PrEP; 4) To design and conduct integrated strategies for HIV prevention. For the first three aims, the HPTN will use a sequential multi-phase drug development strategy for the evaluation of new candidates for prevention. Phase 1 and 2 studies will be conducted for the evaluation of appropriate dose, safety and tolerability of the agent(s). The most promising systemic agents will be advanced using the criteria for a favorable target product profile for new agents including highly effective and durable protection against HIV, minimal adverse effects and drug interactions, high levels of user acceptability, and a high barrier to viral resistance. Efficacious biomedical prevention interventions will be incorporated into integrated strategy study designs that also include socio- behavioral interventions tailored to the HIV prevention imperatives and contextual needs of the specific populations at risk for HIV infection. Socio-Behavioral research (SBR) will be integral to the success of all aspects of the proposed HPTN HIV prevention agenda. Supportive SBR will be used to strengthen biomedical HIV product development (i.e. to inform user preference and ultimately product design for Phase 1-3 clinical trials), while integrative SBR will play a key role in the process of designing and adapting behavioral and structural interventions to complement biomedical interventions in integrated strategy studies. The HPTN will design and conduct the research through collaboration with its scientific leadership, its research teams, community partners, research participants, pharmaceutical companies and funders.

Sincerely,

Greg

From: Dominika Cadotte <DCadotte@fhi360.org>
Sent: Wednesday, July 9, 2025 1:20 PM
To: Wong, Greg (DPH) <greg.wong@sfdph.org>
Subject: RE: For Signature HPTN 113 PO24002400 SFDPH City and County SF - Modification #1

Hi Greg,
I forgot to mention earlier, but you may be able to find some information on the public website. If you search using Award #5UM1AI068619-19, you should be able to confirm that FHI 360 is listed as a recipient of the award.

We all work flexibly and across time zones. I am sending this message at a time that works well for me; please reply at a time that works well for you.

Dominika Cadotte
Contracts and Grants Officer



1825 Connecticut Ave NW
Washington, DC, 20009
dcadotte@fhi360.org
P 1.202.884.8199



fhi360.org | [FHI 360 Facebook](#) | [FHI 360 Twitter](#)

From: Dominika Cadotte <DCadotte@fhi360.org>
Sent: Wednesday, July 9, 2025 1:02 PM
To: Wong, Greg (DPH) <greg.wong@sfdph.org>; Sarah Azimi <SAzimi@fhi360.org>; Gloria Pherribo <GPherribo@fhi360.org>
Cc: Beth Farrell <BFarrell@fhi360.org>; Chiong, Christina (DPH) <Christina.Chiong@sfdph.org>
Subject: RE: For Signature HPTN 113 PO24002400 SFDPH City and County SF - Modification #1

Dear Greg,

Thank you for your email and for raising this question.

Please note that FHI 360 does not share award documentation established between our organization and the funder with external parties. We appreciate your understanding on this matter.

That said, we do have a direct agreement in place with SFDPH. This agreement defines SFDPH and FHI 360 relationship and obligations. If there are any concerns or questions related to that agreement, please don't hesitate to raise them, we would be happy to address them.

Best regards,

We all work flexibly and across time zones. I am sending this message at a time that works well for me; please reply at a time that works well for you.

Dominika Cadotte
Contracts and Grants Officer



1825 Connecticut Ave NW
Washington, DC, 20009
dcadotte@fhi360.org
P 1.202.884.8199



fhi360.org | [FHI 360 Facebook](#) | [FHI 360 Twitter](#)



HPTN GRANT AGREEMENT
BETWEEN
FAMILY HEALTH INTERNATIONAL (FHI 360)
AND

CITY AND COUNTY OF SAN FRANCISCO ("GRANTEE")

HPTN 113 LEADERSHIP GRANT NUMBER: PO24002400

FEDERAL AWARD DATE: June 1, 2006 R&D? : ☒ Yes ☐ No

Name of Grantee: City and County of San Francisco
 Grant Title: HPTN 113
 Grantee TIN/Registration No.: 94-6000417 Grantee UEI Number: DCTNHRGU1K75
 Period of Grant Performance: April 01, 2024 to November 30, 2024
 Total Grant Amount: US \$48,915 Total Obligated Amount: US \$48,915
 Original Sponsor/Funder: NIH/NIAID
 CFDA #: 93.855 CFDA Program Name: Allergy and Infectious Diseases Research
 FHI 360 (Prime) Award: HIV PREVENTION TRIALS NETWORK (HPTN) FHI 360 (Prime) Award No.: UM1 AI068619

FHI 360 Grant Monitor

Name: Sarah Azimi
 Title: Budget Analyst III
 Address: FHI 360 Headquarters
359 Blackwell Street
Durham, NC 27701
 Country: USA
 Tel.: 919-544-7040 ext. [Enter Ext. Number]
 Email: sazimi@fhi360.org

FHI 360 Technical/Program Monitor

Name: Catlin Scoville
 Title: Clinical Research Manager
 Address: 359 Blackwell Street
Durham, NC 27701
 Country: USA
 Tel.: 202-464-3750
 Email: cscoville@fhi360.org

Grantee Point-of-Contact (Administrative Matters)

Name: Sajid Shaikh
 Title: Prin Admin Analyst
 Address: 1380 Howard Street, 4th Fl
San Francisco, CA 94103
 Country: USA
 Tel.: 415-255-3512
 Email: sajid.shaikh@sfdph.org

**Grantee Point-of-Contact
(Technical/Program Matters)**

Name: Susan Buchbinder, MD
 Title: Director of HIV Bridge
 Address: 25 Van Ness Ave, Suite 100
San Francisco, CA 94102
 Country: USA
 Tel.: 415-437-7478
 Email: susan.buchbinder@sfdp.org

In witness of their agreement and their acceptance of the terms and conditions of this Grant, FHI360 and the Grantee have caused this Grant Agreement to be executed by their duly authorized representatives:

Authorized by and accepted for FHI 360:

Signed by: Christy LaTonya Smith 10/4/2024
 Signature: 560D13C44473479... Date
 Christy LaTonya Smith

Name
 Associate Director, Contract Management Services
 Title

Authorized by and accepted for the Grantee:

DocuSigned by: Susan Philip 09/06/2024 | 10:34 AM PDT
 Signature: 4C9D2E27476AA74... Date
 Grant Colfax, MD

Name
 Director of Health
 Title

Approved as to form, David Chiu, City Attorney

By: DocuSigned by:
Henry Lifton
6D6CB58424584B1...

Pursuant to the terms and conditions of the Prime Award cited on the cover page, this Grant Agreement is entered into by and between Family Health International (“FHI 360”) with its headquarters office in Durham, North Carolina, USA and the **City and County of San Francisco** (“Grantee”) with its headquarters in **San Francisco, California, USA**, each a “Party” and, collectively, the “Parties.”

The Parties therefore agree to the following terms and conditions:

ARTICLE 1. PROGRAM DESCRIPTION

The Grantee has been selected by FHI 360 to participate in the **HIV PREVENTION TRIALS NETWORK (HPTN)** to carry out activities under the program described in Attachment A, *Program Description*.

ARTICLE 2. TYPE OF GRANT

This is a Standard Grant that provides the following:

- (a) **TOTAL ESTIMATED AMOUNT.** The total estimated value of this Grant is **US \$48,915**. The Grantee agrees to use its best efforts to implement the program within the total estimated budget in *Attachment B, Budget*.
- (b) **TOTAL OBLIGATED AMOUNT.** This Grant will be incrementally funded by FHI 360. The total obligated funding for this Grant is **US \$48,915** through November 30, 2024. FHI 360 will not reimburse the Grantee for expenses greater than the total obligated amount or for costs incurred outside of the period of performance of this Grant. Changes to obligated funding will be in writing as a modification to this Grant.

ARTICLE 3. CONDITIONS OF FUNDING

- (a) Payment will be on a cost reimbursement basis. FHI 360 will reimburse only those costs that are identified in the approved Grant budget in Attachment B and are determined to be allowable and allocable under the cost principles followed by FHI 360 and provided in 45 CFR Part 75

The cost principles can be downloaded from: www.ecfr.gov

Note: If the Grantee is not able to download, the FHI 360 Grant Officer can make their full text available upon request.

- (b) When incrementally funded, the continued funding of this Grant will be determined by the availability of funds from FHI 360’s donor that is supporting this Grant. FHI 360 is not liable for reimbursing the Grantee or lower-tier grantee for any amount in excess of the total obligated amount, or outside of the Grant period.
- (c) The currency of payment is US dollars.
- (d) Advance payments, if any, shall be in accordance with Article 8 of this Grant.
- (e) When payment by electronic funds transfer is requested, it is the Grantee’s responsibility to provide FHI 360 with the correct banking information.

- (f) Lower-tier Grants are not authorized under this Grant without prior approval from the FHI 360 Grant officer.

ARTICLE 4. INDIRECT COSTS

NEGOTIATED INDIRECT COST RATE AGREEMENT (NICRA)

Grantees may recover applicable indirect costs (i.e., overhead, G&A, etc.) if it is part of the Grantee's usual accounting procedures, consistent with [45 CFR 75.414](#) Indirect (F&A) Costs and Negotiated Indirect Cost Rate Agreement (NICRA) from their U.S. Government cognitive agency.

The Grantee agrees that their indirect cost rate at the time of the invoice submission will not exceed their current rate for current period of performance as approved by their cognizant agency.

ARTICLE 5. COST SHARE REQUIREMENT

Cost share is not required in this Grant.

ARTICLE 6. MONITORING AND REPORTING REQUIREMENTS

TECHNICAL MONITOR. Technical monitoring of this Grant will be performed by the designated FHI 360 Technical/Program Monitor. All Technical Reports will be submitted to the Technical/Program Monitor.

FINAL REPORT. At the conclusion of this Grant, the Grantee will prepare and submit to the FHI 360 Technical/Program Monitor a final report that will summarize the accomplishments of this Grant. The final report will document the results that were obtained, note particular successes as well as approaches that did not achieve the anticipated result(s). The final report is due 30 days after the end of the grant.

AUDIT REPORT.

- (a) U.S. Grantees must have an annual audit conducted in accordance with 45 CR 75 Subpart F. The Grantee must submit a copy of the audit report to the FHI 360 Technical Monitor within thirty (30) days of its completion, but no later than nine (9) months after the end of the period audited.
- (b) FHI 360 is responsible for ensuring accountability of NIH funding. FHI 360 maintains the right to review the Grantees records and arrange for an annual independent audit to be conducted, financed directly by FHI 360.

ARTICLE 7. FINANCIAL REPORTING

FINANCIAL REPORTS. For each Grant, the Grantee will prepare and submit to the FHI 360 Grant Monitor (listed on the Face Page of this document) a monthly financial report within 30 days after the close of the period in accordance with the payment instructions included in the Grant. Only allowable expenses that are authorized by each Grant will be approved.

The Grantee is required to submit financial reports following the format specified in Attachment C, *Subrecipient Financial Report (SFR)*. The Grantee will submit a labor summary, providing a list of employees by name, position title, and salary paid during the period reported. The

Grantee also will submit a detailed transaction list itemizing for all other reported expenses during the period.

Grantee must submit Subrecipient Financial Report (SFR) with appropriate backup detail for payment to:

(a) HPTN Invoice at email address: HPTNINVOICE@FHI360.org
Include "HPTN" in the subject line of the email.

OR

(b) FHI 360
Attention Gloria Pheribo: HPTN
359 Blackwell Street, Suite 200
Durham, NC 27701

ARTICLE 8. PAYMENT PROCEDURES

(a) Advance payments are not authorized under this Grant.

(b) On submission of the claim for final payment, the Grantee must certify in writing to the FHI 360 Technical/Program Monitor that the Grant is completed, and the Grantee will make no further claim against FHI 360 after final payment.

ARTICLE 9. APPLICABLE REGULATIONS AND REQUIREMENTS

The Grant is funded under the Prime Award, Grant Number UM1 AI068619 between FHI 360 and the National Institute of Allergy and Infectious Diseases (NIAID), National Institutes of Health. The Grantee is subject to 45 CFR Part 75, the NIH Grants Policy Statement, and the sponsor specific requirements that are set forth in Attachment E *HPTN NIH Flow-Down Terms and Conditions* and are incorporated herein by reference.

ARTICLE 10. FHI360 GRANT TERMS AND CONDITIONS

The Grant Terms and Conditions governing this Grant are set forth in **Attachment D**, FHI 360 Grant Terms and Conditions and are hereby incorporated into this Grant by reference.

FHI 360 Contracts Point of Contact

The FHI 360 Contracts Specialist Point of Contact for this award is:

Jackson Lee
Contracts Specialist II
Contract Management Services
FHI 360
359 Blackwell St., Ste 200
Durham, NC 27701
JLee@fhi360.org
919-321-3715

FHI 360 Grant Officer

The FHI 360 Grant Officer for this award is:

Christy Smith
Contracting Officer
Contract Management Services
FHI 360
359 Blackwell St, Ste 200
Durham, NC 27701
CFoster@fhi360.org
919-321-3467

ARTICLE 11. SPECIAL AWARD CONDITIONS

a) COI Requirements Promoting Objectivity in Research Applicable to Grantees (42 CFR Part 50 Subpart F)

42 CFR Part 50. 604 requires that institutions conducting PHS-funded research “*Maintain an up-to-date, written, enforced policy on financial conflicts of interest.*” Further, “*If the Institution carries out the PHS-funded research through a Grantee (e.g., subcontractors or consortium members), the Institution (awardee Institution) must take reasonable steps to ensure that any Grantee Investigator complies with this subpart by incorporating as part of a written agreement with the Grantee terms that establish whether the financial conflicts of interest policy of the awardee Institution or that of the Grantee will apply to the Grantee's Investigators.*”

Choose the applicable checkbox:

- ☐ Grantee organization/institution does not have an active and/or enforced conflict of interest policy and hereby agrees to abide by NIH HIV/AIDS Clinical Trials Networks Financial Disclosure Policy and Procedure. The NIH HIV/AIDS Clinical Trials Networks Financial Disclosure and Conflict of Interest Guidelines: Standard Operating Procedures are located at

<https://www.hptn.org/resources/manual-of-operations>

Note: The FHI 360 Grant Officer will provide this policy upon your request.

- ☒ Grantee organization/institution hereby certifies that it has an active and enforced conflict of interest policy that is consistent with the provision of 42 CFR Part 50, Subpart F, “Responsibility of Applicants for Promoting Objectivity in Research.” Grantee also certifies that, to the best of Institution knowledge (1) all financial disclosures have been made related to the activities that may be funded by or through a resulting agreement, and required by its conflict of interest policy; and (2) all identified conflicts of interest have or will have been satisfactorily managed, reduced or eliminated in accordance with Grantee’s conflict of interest policy prior to the expenditure of any funds under any resulting agreement.

Reporting Requirements

Grantee shall report any financial conflict of interest to the Grants Officer of FHI 360. Any financial conflicts of interest identified shall subsequently be reported to NIH. Such report shall be made before expenditure of funds authorized under this Grant and within 30 days of any subsequently identified financial conflict of interest.

b) **Work Involving Human or Vertebrate Animals** (Select Applicable Options)

☒ Human Subjects ☐ Vertebrate Animals ☐ No Human or Vertebrate Animals

Subrecipient agrees that any non-exempt human and/or vertebrate animal research protocol conducted under this Subaward shall be reviewed and approved by its Institutional Review Board (IRB) and/or its Institutional Animal Care and Use Committee (IACUC), as applicable and that it will maintain current and duly approved research protocols for all periods of the Subaward involving human and/or vertebrate animal research. Subrecipient certifies that its IRB and/or IACUC are in full compliance with applicable state and federal laws and regulations. The Subrecipient certifies that any submitted IRB / IACUC approval represents a valid, approved protocol that is entirely consistent with the Project associated with this Subaward. In no event shall Subrecipient invoice or be reimbursed for any human or vertebrate animals related expenses incurred in a period where any applicable IRB / IACUC approval is not properly in place.

c) **Human Subjects Data** (Select One)

☒ Not Applicable
☐ Applicable
☐ Human subjects data will not be addressed in this agreement

Complete the below if the Applicable option is chosen.

Human Subject Data will be exchanged under this Subaward (check all that apply):

☐ From Subrecipient to FHI 360
☐ From FHI 360 to Subrecipient

FHI 360 will set forth the terms of the exchange of Human Subjects Data (Select One):

☐ In the Special Award Terms and Conditions of this Subagreement
☐ Via a separate Data Use Agreement

Please refer to the HPTN Manual of Operations at the following site for further information:

<https://www.hptn.org/resources/manual-of-operations>

If you have additional questions you can also contact your FHI 360 Program/Technical Monitor.

ARTICLE 12. TITLE TO AND USE OF PROPERTY

Title to equipment costing US\$5,000 or more that is purchased or fabricated with research funds or Grantee cost sharing funds, as direct costs of the project or program, shall vest with the Grantee upon acquisition. Management of the property is subject to the conditions specified in 45 CFR 75.320(d).

- (a) The Grantee is responsible for the care, maintenance, and security of the equipment or property purchased under this Grant.
- (b) The Grantee must maintain property records and be reconciled with the results of a physical inventory at least every 2 years.
- (c) The Grantee is required to immediately report theft, loss, or damage to Grant-funded equipment or property to the FHI 360 Grant Officer.

(d) Used equipment may not be purchased with Grant funds.

ARTICLE 13. ORDER OF PRECEDENCE

Any conflict between any of the provisions and attachments to this Grant shall be resolved by applying the following order of precedence:

- (a) Articles of this Grant;
- (b) Attachment A – Program Description; and
- (c) Attachment B – Budget Summary

- (d) Attachment D – FHI 360 Grant Terms and Conditions; and
- (e) Attachment E – HPTN NIH Flow-Down Terms and Conditions

End of Section-

ATTACHMENTS

ATTACHMENT A – PROGRAM DESCRIPTION
ATTACHMENT B – BUDGET
ATTACHMENT C – SUBRECIPIENT FINANCIAL REPORT
ATTACHMENT D – FHI 360 GRANT TERMS AND CONDITIONS
ATTACHMENT E – HPTN NIH FLOW-DOWN TERMS AND CONDITIONS



ATTACHMENT A PROGRAM DESCRIPTION

1. Objectives

The purpose of this agreement is to provide **10%** level of effort salary support for **Dr. Buchbinder** as the HPTN Chair of HPTN 113, *“Double Prevention: A Vanguard Study of an Integrated Strategy of HIV PrEP and STI PEP for Young Latino Gay, Bisexual, and other Cisgender Men who have Sex with Men in the Americas.”* In this role, **Dr. Buchbinder** will provide scientific leadership in the development, implementation, and day-to-day oversight and conduct of the **HPTN 113** protocol.

The primary study objectives:

- To determine the efficacy of the 3P mHealth package on PrEP uptake among Latino MSM in the Americas
- To determine the efficacy of the 3P mHealth package on PrEP adherence among Latino MSM in the Americas
- To assess DoxyPEP uptake, use, and acceptability, and factors associated with each

The main purpose of this study is to adapt and test a suite of mHealth tools to increase HIV pre-exposure prophylaxis (PrEP) uptake and adherence among young Latino gay, bisexual, and other cis-gender men who have sex with men (MSM) and evaluate the uptake, adherence, and acceptability of doxycycline for sexually transmitted infection (STI) post-exposure prophylaxis (DoxyPEP).

2. KEY DELIVERABLES

As the Chair for **HPTN 113**, in close collaboration with other protocol team members, **Dr. Buchbinder’s** responsibilities include:

- Actively participating in the protocol development process, bringing the approved concept to Protocol V1.0, including
 - Attending protocol development meetings
 - Participating in protocol reviews, including reviews by the Scientific Review Committee (SRC) and the DAIDS Prevention Sciences Review Committee (PSRC)
 - Responding to reviewer comments
- Providing site training and leadership, including preparation of materials for training
- Providing overall leadership to ensure that the study meets its projected accrual and retention goals within the specified timeframes.
- Facilitating decision-making within the protocol team to achieve agreement on scientific or operational issues; if agreement cannot be reached, referring the issue to the HPTN leadership for consideration.
- Participating in review of operational and safety data once the trial begins, as necessary.
- Participating in *ad hoc* review of safety data (AEs, SAEs, social harms), as required.
- Actively participating in drafting the primary endpoint manuscript once the trial is complete; the study Chairs are expected to serve as the lead authors on the writing team; the expectation is that a draft manuscript of the primary endpoint analyses will be completed within six months after the trial data for primary endpoints are finalized.
- Representing the HPTN and the study at meetings and conferences, if needed.
- Participating in site visits as needed.

Payment will be made to the Grantee upon submission of invoices to Family Health International. Funding for subsequent periods of performance, if necessary, is contingent upon satisfactory performance and additional funding from NIAID.

ATTACHMENT B
BUDGET



Subawardee:	City and County of San Francisco	Start Date:	4/1/2024
PO#	PO24002400	End Date:	11/30/2024
Subaward title:	HPTN 113 Leadership (Buchbinder)		

	Current Funding Period Obligation	Total Obligation	Total Life of Project
	Apr 1 2024 - Nov 30 2024	Apr 1 2024 - Nov 30 2024	Apr 1 2024 - Nov 30 2024
	Amount	Amount	Amount
	USD	USD	USD
1. SALARIES	29,587	29,587	29,587
2. FRINGE BENEFITS	10,356	10,356	10,356
3. CONSULTANTS	-	-	-
4. EQUIPMENT	-	-	-
5. TRAVEL/TRANSPORTATION	-	-	-
6. SUBAWARDS	-	-	-
7. OTHER DIRECT COSTS	-	-	-
8. INDIRECT COST/G&A	8,972	8,972	8,972
TOTAL PROJECT COSTS	48,915	48,915	48,915



This report must be submitted to FHI 360 in accordance with the subaward's financial reporting requirements and indicated due dates.

Reporting Cycle (check one):

☒ Monthly☐ Quarterly☐ Other _____

Subaward Title: HPTN 113 Leadership (Buchbinder)

Please note that all required supporting documentation per the Terms & Conditions of the subaward must be attached to this form.

		Amount
Funds Previously Received	Wire/Check No	
Funds Received this Period		
Total Funds Received from FHI 360		
Total Amount Expended		
Balance on Hand		
Total Interest Earned		

I certify that to the best of my knowledge and belief, this Financial Report is a correct, complete and accurate statement, that my organization is properly entitled to payment, and that all amounts requested are for appropriate purposes in strict accordance with the terms and conditions of the subaward.

<i>Typed name, Title</i>	<i>Signature</i>	<i>Date</i>
--------------------------	------------------	-------------

<i>Typed name, Title</i>	<i>Signature</i>	<i>Date</i>
--------------------------	------------------	-------------

SUBAWARDEE FINANCIAL REPORT (SFR)

The Subawardee Financial Report must be submitted to FHI 360 in accordance with the terms and conditions of the Grant. All amounts must be entered in the same currency and in accordance with the terms and conditions of the Grant.

Note: if using the electronic version of this report, input should be entered into the shaded areas. Other areas are calculations.

HEADER SECTION

Submit Reports to:	Enter the name and FHI 360 office & city where the report is submitted.
ID/FCO No.:	Enter the ID/FCO Number shown in the Grant document.
Reporting Period:	Enter the period / dates covered by the report (month and year).
Subaward Start Date:	Enter the start date of the Grant according to the Grant document.
Today's Date:	Enter the day in which the report is completed.
Subaward End Date:	Enter the end date of the project based on the Grant or latest amendment / modification.
Currency:	Enter the type of currency used to report all financial information. This currency should be in accordance with the terms and conditions of the Grant.
Subawardee Name:	Enter the Grantee name as shown in the Grant document.
Project Title:	Enter the project name as shown in the Grant document.
Reporting Cycle:	Indicate the reporting cycle as indicated in the Grant document.

I. BUDGET ANALYSIS

Current Obligations:	Enter the budget amount for each line item reflected on the Summary Budget in the latest Grant document. The budget amount for each line item must be in the currency indicated in the Grant document.
Total Expenses Previously Reported:	Enter the <i>Total Expended to Date</i> amounts in each line item from the previous report.
Expended This Reporting Period:	Enter the amount spent during the period covered by this report into the respective line items.
Total Expended to Date:	Enter the sum of <i>Total Expenses Previously Reported</i> and <i>Expended This Reporting Period</i> .
Obligated Funds Remaining:	Enter the <i>Current Obligation</i> less <i>Total Expended to Date</i> .
Total USD:	Enter the total current obligation in US dollars reflected on the Summary Budget in the latest Grant document.
Subaward Exchange Rate:	Enter the exchange rate used to convert US dollars to the currency used for reporting, if applicable. The rate is for INFORMATIONAL PURPOSES ONLY to show the conversion between the two currencies if applicable. This rate should match the rate on the Summary Budget of the latest Grant document (it is suggested that it be linked to the Summary Budget page if possible).
***Attachments Required	For budget categories marked with an asterisk (*), attach an itemized list of expenditures for the reporting period: Example: 1. <u>Salaries</u> require a list of employees by name, position title, and salary paid during the period. The amount charged should reflect ACTUAL hours spent on the project and not merely the BUDGETED level of effort. A labor report detailing specifics is required. 2. <u>Fringe Benefits</u> require a schedule of benefits/allowances given to employees.

- 3. **Consultants and professional fees** requires a list of payments made during the period indicating the name of the payee, daily rate, total paid, and a brief description of the services performed.
- 4. **Procurement** requires a description of the equipment, vendor name, amount paid, and the date of purchase.
- 5. **Other Direct Costs** requires a schedule of all direct costs associated with project activities that are not allocated to the categories above.
- 6. **Other** requires a description of other allowable costs in accordance with the Grant document. The type of expense must be specified.

II. SUMMARY OF FUNDS

Funds Previously Received:	Enter the amount received as of the beginning of the period. This amount should be equal to the Total Funds Received from FHI 360 line on the previous report.
Funds Received this Period:	Enter the amount of all wires or checks received this period. Upon review, FHI 360 Finance will enter the US dollar equivalent amount based on General Ledger information.
Wire/Check No.:	Enter the wire or check number from funds received.
Total Funds Received from FHI 360:	Enter the sum of <i>Funds Previously Received</i> line and the <i>Funds Received this Period</i> line.
Total Amount Expended	Enter the total amount in the <i>Total Expended to Date</i> column above.
Balance on Hand	Enter the differences between the Total Funds Received from FHI 360 and the Total Amount Expended lines. This should equal the total cash on hand at the end of the period. All unspent funds are to be returned to FHI 360 within the period stated in the Grant.
Interest Earned	Record interest earned if the bank account earns interest. Grantee is allowed to keep \$250 annually to cover administrative expenses
USD Current Obligated Amount	Enter the total current obligation amount in US dollars shown in the Grant or current amendment. This should be the same as the <i>Total USD</i> amount above.
USD Obligation Remaining:	Enter the US Current Obligated Amount less Total Funds Received from FHI 360 (US dollars).
Total USD Obligation Less USD Sent as of this Rpt:	
Note: FHI 360 Finance will enter amounts in US dollars based on FHI 360's General Ledger. This information will be communicated to the Grantee periodically to compare against the US dollar amount in the Grant as the US dollar amount prevails in a majority of the Grants. The current bank rate should be used when converting the balance on hand to estimated US dollar equivalent.	

III. CERTIFICATION AND APPROVALS

Certification and approval:	This report must be certified and signed by the Grantee's Authorized Official and approved by FHI 360's Technical/Program	Monito
Review:	In addition to being approved by FHI 360's Technical/Program Monitor, this report must also be reviewed by the FHI 360 Finance department.	



ATTACHMENT D

NEGOTIATED FHI 360 GRANT TERMS AND CONDITIONS FOR CITY AND COUNTY OF SAN FRANCISCO

1. INDEPENDENT ENTITY

The relationship of the Grantee to FHI 360 is that of an independent entity, and nothing in this Grant will be construed as creating any other relationship. As such, the Grantee will comply with all laws and assume all risks incident to its status as an independent entity. This includes, but is not limited to, responsibility for all applicable income taxes, associated payroll and business taxes, licenses and fees, and such insurance as is necessary for the Grantee's protection in connection with work performed under this Grant. Neither the Grantee nor anyone employed by it will be, represent, act, purport to act, or be deemed to be an agent, representative, or employee of FHI 360.

This Grant is funded in whole or in part with funds from the funding sponsor. Neither the funding sponsor nor any of its departments, agencies, or employees is or will be a party to this Grant. All communications regarding this Grant must be directed to FHI 360.

2. CONFIDENTIAL INFORMATION

During the term of this Grant, the Grantee and its employees may receive or have access to data and information that is confidential and proprietary to FHI 360 or the funding sponsor.

"Confidential Information" is defined as all technical information whether directly or indirectly disclosed, in verbal, written, graphic, photographic, electronic, prototypic, sample or any other form.

Confidential Information disclosed in written, graphic or electronic format will be marked on its face as "Confidential" and/or "Proprietary." *Confidential Information* disclosed in verbal or visual form will be summarized in writing and confirmed to the Grantee as "Confidential" and/or "Proprietary" within thirty (30) days following disclosure.

Confidential Information does NOT include information that:

- is or becomes generally available to the public other than as a result of a disclosure by the Grantee;
- becomes available to the Grantee on a non-confidential basis from a source that is not prohibited by a legal, contractual or fiduciary obligation from disclosing such information;
- is developed independently by the Grantee without use of *Confidential Information*, as demonstrated by written records and evidence;
- was in the Grantee's possession or known to the Grantee prior to receipt from the disclosing party; or
- is required by law to be disclosed, provided the Grantee notifies FHI 360 promptly and gives FHI 360 an opportunity to seek an appropriate protective order.

Confidential Information may be used by the Grantee or its employees only for purposes of performing the obligations under this Grant. The Grantee will not reveal, publish or otherwise disclose Confidential Information to any third party without the prior written consent of FHI 360.

All *"Confidential Information"* disclosed to or otherwise made known to the Grantee as a result of services under this Grant remains the sole property of FHI 360 and/or its funding sponsor.

These obligations of confidentiality and non-disclosure will remain in effect for a period of five (5) years after the termination of this Grant.

3. ORGANIZATIONAL CONFLICTS OF INTEREST

- a) The Grantee represents that, to the best of its knowledge and belief, there are no relevant facts or circumstances which could give rise to an organizational conflict of interest, or that the Grantee has disclosed all such relevant information.
- b) The Grantee agrees that if an actual or potential organizational conflict of interest is discovered after award, the Grantee will make a full disclosure in writing to the FHI 360 Grant Officer. This disclosure will include a description of activities which the Grantee has taken or proposes to take, after consultation with the FHI 360 Grant Officer, to avoid, mitigate, or neutralize the actual or potential conflict.
- c) Remedies – The FHI 360 Grant Officer may terminate this Grant for convenience, in whole or in part, if it deems such termination necessary to avoid an organizational conflict of interest. If the Grantee was aware of a potential organizational conflict of interest prior to award or discovered an actual or potential conflict after award and did not disclose or misrepresented relevant information to the FHI 360 Grant Officer, FHI 360 may terminate the Grant for default.
- d) The Grantee further agrees to insert provisions which will conform substantially to the language of this clause, including this subparagraph (d), in any lower-tier Grants arising out of this Grant.

4. STANDARDS OF ETHICS AND BUSINESS CONDUCT

The Grantee acknowledges and accepts FHI 360's emphasis on the importance of accountability to those who benefit from FHI 360's work, and the parties' mutual accountability to those who benefit from FHI 360's work, and the parties' mutual accountability to each other, to project collaborators, and to our sponsors. The Grantee confirms its accountability to participants in FHI 360 programs, children, any vulnerable populations and to all others whom its programs are intended to serve.

4.1 Combating Trafficking in Persons: FHI 360 requires that the Grantee uphold the principles of FHI 360's Combating Trafficking in Persons policy (located on the FHI 360 Ethics and Safeguarding website at <https://www.fhi360.org/ethics-safeguarding/#our-policies-and-supplemental-guidance>). Grantee and its personnel must refrain from and take steps to prevent any conduct that violates the policy. Grantee or grantee personnel who witness conduct prohibited by the policy or who identify that Grantee personnel have engaged in such conduct should promptly report the conduct orally or in writing within 24 hours (or as soon as possible under the circumstances) to the FHI 360 Office of Compliance and Internal Audit (OCIA) by **one** of the following means: (1) via email at compliance@fhi360.org; (2) via OCIA's Ethics and Compliance Hotline: 1-800-461-9330 in the U.S or Country-specific hotline numbers listed on FHI 360's reporting website; Skype: +1-800-461-9300; or Country-specific hotline numbers listed on FHI 360's reporting website; or (3) via OCIA's anonymous reporting website (<http://www.fhi360.org/anonreportregistry>). FHI 360 requires all Suppliers and Supplier personnel to cooperate fully with investigations of policy violations and provide truthful information to investigators. In addition, Grantee must comply with any funder requirements incorporated into this grantee. Failure to comply with this provision may result in termination of this grant.

4.2 Safeguarding of Children in FHI 360 Programs: Grantee must uphold the principles of the FHI 360 Safeguarding of Children policy located on the FHI 360 Ethics and Safeguarding website at <https://www.fhi360.org/ethics-safeguarding/#our-policies-and-supplemental-guidance>) and will undertake to ensure that no individual with any history of crimes against children will be placed in a position involving direct interaction with children as part of the work under this Grant. The Grantee and any employees, consultants, and volunteers of the Grantee ("*Grantee Personnel*") are prohibited from engaging in child abuse, exploitation, or

neglect in its programs and activities, including without limitation, physical abuse; emotional ill-treatment; neglect or insufficient supervision; sexual abuse; exploitation through prostitution or production of pornographic materials; trafficking; or commercial, transaction or labor exploitation resulting in actual or potential harm to the child's health, well-being, survival, development or dignity. The Grantee Personnel must comply fully with host country and local child welfare and protection laws or with international standards, whichever gives greater protection, and must comply with US laws where applicable.

4.3 Protecting Program Participants from Sexual Exploitation and Abuse (SEA): The Grantee must uphold the principles of the *United Nations Interagency Standing Committee on Protection from Sexual Exploitation and Abuse in Humanitarian Crises* and FHI 360's policy on Protecting Program Participants from Sexual Exploitation and Abuse, located on the FHI 360 Ethics and Safeguarding website at <https://www.fhi360.org/ethics-safeguarding/#our-policies-and-supplemental-guidance>). Grantee and Grantee Personnel are prohibited from committing any form of sexual exploitation or abuse of any adults or children who are served by FHI 360 programs or encounter Grantee Personnel engaged in activities under this Agreement ("*Program Participants*"). Sexual exploitation means any actual or attempted abuse of Program Participants that takes advantage of their position of vulnerability or trust for sexual purpose. Sexual abuse means any actual or threatened physical intrusion of a sexual nature by force or under unequal or coercive conditions. Grantee must take steps to develop a culture that does not tolerate SEA and prevent, detect, and/or stop any SEA by Grantee Personnel.

4.4 Violence Within the Work Environment: The Grantee must uphold the principles of FHI 360's Violence-Free Workplace policy located on the FHI 360 Ethics and Safeguarding website <https://www.fhi360.org/ethics-safeguarding/#our-policies-and-supplemental-guidance>) and take steps to prohibit and prevent any form of violence or threats of violence in the work environment, by or against any Grantee Personnel while on the Grantee's premises or work locations of the Grantee, at any events sponsored by the Grantee or while engaged in the performance of employment duties for Grantee whether on or off the Grantee's premises. The Grantee's policy must prohibit Grantee Personnel from perpetrating any form of violence or threats of violence against any staff or any Grantee partner, Grantee, or client; program participants; or anyone else with whom they interact in work-related situations.

4.5 Harassment-Free Work Environment: Grantee must uphold the principles of FHI 360's Harassment-Free Work Environment policy located on the FHI 360 Ethics and Safeguarding website at <https://www.fhi360.org/ethics-safeguarding/#our-policies-and-supplemental-guidance>) and take steps to prohibit and prevent Grantee Personnel are prohibited from engaging in any form of harassment in the workplace or work-related situations based on: race, color, ethnic or national origin, religion, age, sex, sexual orientation, gender identity, or perceived adherence to socially defined norms of masculinity and femininity, medical conditions, pregnancy, childbirth, and breastfeeding, nationality or citizenship, physical or mental disability, genetic information or characteristics (or those of a family member), protected U.S. military or U.S. veteran status, status as a victim of domestic violence, sexual assault or stalking, and/or any other class, status, or characteristic protected by local law. The Grantee must strictly prohibit Grantee Personnel from harassing any Grantee Personnel, employees of any Grantee partner, Grantee, or client; program participants; or anyone else with whom the Grantee Personnel interact in work-related situations.

4.6 Dealing with Governments or Officials; Compliance with Foreign Corrupt Practices Act: The Grantee acknowledges that FHI 360 corporate policy located on the FHI 360 Ethics and Safeguarding website at <https://www.fhi360.org/ethics-safeguarding/#our-policies-and-supplemental-guidance>) requires that FHI 360's activities be conducted within the letter and spirit of the law. The Grantee, including any of its affiliates and their respective employees, agents officers, or other members of its management will not make any payment, either directly or indirectly, of money or other assets to government or political party officials, candidates for public

office, or representatives of other businesses or persons acting on behalf of any of the foregoing (referred to collectively as “officials”) where such payment would constitute a violation of any law. In addition, regardless of legality, the Grantee will make no payment either directly or indirectly to officials if such payment is for the purpose of influencing decisions or actions with respect to the subject matter of this Grant or any other aspect of FHI 360’s operations.

4.7 Reporting of any Violations: For any referenced policies in Section 4 of this document that have a reporting requirement for Suppliers (which includes subrecipients), the Grantee and Grantee Personnel who observe, suspect, receive allegations of misconduct or violations of any of the above referenced policies and requirements in section 4 of this document are required to report the conduct immediately, either orally or in writing by contacting The Office of Compliance and Internal Audit (OCIA) via email at compliance@fhi360.org and OCIA’s Ethics and Compliance Hotline (1-800-461-9330 in the US or Country-specific hotline numbers listed on FHI 360’s reporting website), OCIA’s reporting website either with your name or anonymously at (<http://www.fhi360.org/anonreportregistry>). Please note that anonymous reports are generally more difficult to investigate due to limited information. When reporting, individuals are urged to provide as much detail as possible about the conduct, if possible, including identifying people who were involved or who witnessed the conduct, so long as this will not put the persons identified at risk of immediate harm. The Grantee must maintain policies that require Grantee Personnel to report any misconduct or violations to any other appropriate management within the Grantee’s organization, with any appropriate law enforcement agency or other regulatory agency as required by local laws.

4.8 Consequences of Violations: Violations by the Grantee or Grantee Personnel and/or the failure to follow the requirements of the policy may result in immediate termination of Grantee's award. FHI 360 may pursue any contractual or other legal or equitable remedies that may be available.

5. PROTECTION OF HUMAN RESEARCH SUBJECTS

The Grantee is responsible for safeguarding the rights and welfare of human subjects involved in research under this Grant. The Grantee shall provide FHI 360 with written assurance satisfactory to the sponsoring federal department or agency that it will comply with the Common Federal Policy for the Protection of Human Subjects found in 22 CFR 225 of the Code of Federal Regulations. This policy applies to all research involving human subjects conducted, supported or otherwise subject to regulation by any federal department or agency including research that takes place in foreign countries. In the case of research conducted outside of the United States and remains subject to 22 CFR 225, the Grantee shall submit to the FHI 360 Technical/Program Monitor written assurance that procedures followed by the Grantee to protect human research subjects are at least equivalent to those in 22 CFR 225. In lieu of a written assurance, FHI 360 shall accept the existence of a current assurance, appropriate for the research in question, on file with the Office for Human Research Protections, HHS, or any successor office, and approved for federal wide use by that office.

Any research supported under this Grant that will involve human subjects as defined in 22 CFR 225 shall not commence until the required assurance has been submitted to FHI 360 and Grantee has been notified in writing by the FHI 360 Technical/Program Monitor that all other requisite approvals of the Grantee’s procedures pursuant to the protection of human research subjects have been obtained, as appropriate.

6. RESEARCH INTEGRITY AND MISCONDUCT

FHI 360 requires that research is conducted with the highest standards of integrity and ethical behavior regardless of the funding source or type of research. FHI 360 employees and related personnel have a personal responsibility for implementing FHI 360’s Research Integrity and Misconduct policy. The policy requires anyone having reason to believe that a person has engaged in research misconduct to report his/her concern of possible research

misconduct to the FHI 360 Research Integrity Officer (RIO). When research is supported by the Public Health Service (PHS), National Science Foundation (NSF) and other Federal Agencies FHI 360 complies with special reporting requirements found in PHS Policies on Research Misconduct – 42 CFR Part 93 and NSF regulations at 45 CFR 689. FHI 360 subawardees and subcontractors are responsible for handling research misconduct in compliance with applicable federal regulations, local laws and agreement terms and conditions. In addition, FHI 360 subawardees and subcontractors are expected to inquire into, and if necessary, investigate and resolve promptly and fairly all instances of alleged research misconduct related to the subaward or subcontract, such review to comply with applicable federal regulations, local laws, and agreement terms and conditions. For determinations of research misconduct while engaged in FHI 360 research activities, subawardees and subcontractors are required to provide a report to the RIO that details the facts and analysis that supports the conclusion, identifies the type of research misconduct, describes any mitigating steps and/or administrative and disciplinary actions taken, list all individuals and/or organizations notified, includes any supporting documentation of the misconduct, and provides any other relevant information pertinent to the investigation. At the discretion of the RIO, the RIO may take custody of all research records and evidence to meet any applicable legal and/or regulatory requirements.

7. PATIENT CARE

The Grantee assumes full responsibility and liability for the care and treatment of its patients. To the extent that the training and other support provided to the Grantee by FHI 360-employed personnel under this Grant encompasses treatment of Grantee's patients, the Grantee acknowledges and agrees as follows:

- (a) that the Grantee is ultimately responsible for such treatment;
- (b) that such treatment will be deemed to be done by and on behalf of the Grantee;
- (c) that the Grantee waives any claim against FHI 360 and/or FHI 360-employed personnel arising out of patient treatment;
- (d) that the Grantee will assume full responsibility for any claims made by patients arising out of patient treatment, whether patient treatment was provided by Grantee-employed personnel or by FHI 360-employed personnel; and,
- (e) that the Grantee will hold FHI 360 harmless from any liability arising out of any assistance provided under the terms of this Grant.

8. INSPECTION AND ACCEPTANCE

Acceptance of the effort specified in the Program Description will be made by FHI 360's Technical/Program Monitor or his/her authorized representative. FHI 360 has the right to inspect and evaluate the activities performed under this Grant at all reasonable times and in a manner that will not unduly delay the activities.

All required deliverables will be submitted to the FHI 360 Technical/Program Monitor. Notwithstanding any other payment provision of this Grant, failure of the Grantee to submit required reports when due, or failure to perform or deliver required activities will result in the withholding of payment under the Grant unless such failure arises out of causes beyond the control and without the fault or negligence of the Grantee.

9. CHANGES AND MODIFICATIONS

Any proposed change to this Grant must be authorized by a written modification to this Grant before performance of the change may begin. Any effort undertaken by the Grantee pursuant to oral instructions or technical directions issued other than in accordance with the provisions of this Grant will be at the Grantee's risk of performing activities outside the Program Description of this Grant and may not be eligible for payment of the costs incurred.

10. SUBGRANTS

The Grantee will not execute Subgrants under this Grant without the prior written approval of the FHI 360 Grant Officer. The Grantee will submit to the FHI 360 Grant Officer information concerning the need for Subgrants including an assessment of the reasonableness of the costs to be paid to any Subgrantee. A copy of any proposed Subgrant must accompany the request for approval.

11. WORKING FILES AND DATASETS

The Grantee certifies that any working files maintained by the Grantee including calculations, assumptions, interpretations of regulations, sources of information, and other raw data required in the performance of this Grant will be maintained in an accurate and complete manner. Upon request, the Grantee will provide information contained in its working files to the FHI 360 Technical/Program Monitor.

12. RECORDKEEPING AND ACCESS

The Grantee will maintain books, records, documents, program and individual service records and other evidence of its accounting and billing procedures and practices which sufficiently and properly reflect all direct and indirect costs of any nature incurred in the performance of this Grant. These records will be subject at all reasonable times to monitoring, inspection, review or audit by authorized employees or agents of FHI 360 or its funding sponsor. The Grantee will retain all such records concerning this Grant for a period of three (3) years after the submission of the final financial report, unless a longer period is specified in the specific terms and conditions of the Grant and for U.S. Government funded grants, for a longer period if there is an applicable exception under 45 CFR 75.361. If any litigation, claim or audit is started before the expiration date of this three-year period, the records will be retained until all litigation, claims or audit findings involving the records have been resolved.

13. PUBLICATION

Unless otherwise specified in this Grant, the Grantee is encouraged to publish the results of its work under this Grant.

In the event the Grantee proposes any *academic* publication arising out of the Grantee's work under this Grant, the Grantee agrees to comply with HPTN Publication Policy that can be found at the following site:

<https://www.hptn.org/resources/manual-of-operations>

Disclaimer.

For both *academic* and *non-academic* publications resulting from work performed under this Grant, the Grantee will include a disclaimer which is in substantially conformity with the following example:

“This publication was prepared under a Grant funded by Family Health International under Cooperative Agreement/Grant No. UM1 AI068619 funded by the National Institutes of Health. The content of this publication does not necessarily reflect the views, analysis or policies of FHI 360 or the National Institutes of Health, nor does any mention of trade names, commercial products, or organizations imply endorsement by FHI 360 or the National Institutes of Health.”

The Grantee will notify the FHI 360 Technical/Program Monitor when any article, chapter or other publication is published, and will provide a copy of the published work to FHI 360.

14. TERMINATION

- a) ***Termination.*** Funding for this Grant is contingent upon factors including the availability of funds to FHI 360, satisfactory progress by the Grantee, and overall direction of the program of which this Grant is a part. Either party may terminate this Grant at any time by providing five (5) calendar days written notice prior to the

effective date of the suspension or termination to the Grantee. The Grantee will be responsible for satisfying all of its obligations relative to this Grant through the effective date of termination. FHI 360 will only be responsible for costs incurred after the effective date of suspension or termination as follows: (a) FHI 360 expressly authorizes such costs in the notice of suspension or termination or subsequently in writing, or (b) the costs result from non-cancelable obligations that were properly incurred before the effective date of suspension or termination, were incurred not in anticipation of the suspension or termination, and the costs would be allowable if the Grant were not suspended or expired normally at the end of the funding period in which the termination takes effect.

b) **Terms upon Termination.** Upon termination, the Grantee will:

1. cease all work except to the extent that is minimally necessary to shut down operations;
2. return or provide to FHI 360 all materials and work product related to this Grant; and,
3. provide FHI 360 with such services related to the transfer of tasks under the Program Description to another Grantee as may be specified by FHI 360 upon termination.

The Grantee will be reimbursed for services provided up to the effective date of termination and any such transfer costs as are specified and approved in advance by FHI 360, provided such services are in accordance with the provisions of this Grant.

15. DISPUTES

All disputes and differences that may arise out of or in connection with the terms of this Grant will be settled by direct discussions between the FHI 360 Grant Officer and the Grantee's duly authorized representative. If after sixty (60) days resolution has not been reached, either party may exercise their legal right to any available remedy in a court of law

16. INDEMNIFICATION

The Grantee will indemnify, defend, and hold FHI 360 harmless from any loss, damage, liability, claims, costs, demands, suits, or judgments, including reasonable attorney's fees, as a result of any damage or injury to the Grantee, its employees, officers, or agents, or injury to the property of the Grantee, its employees, officers, or agents, or for any injury to third persons or their property which is directly or indirectly caused by the Grantee, its employees, officers, or agents, in the course of performance of any of the work specified in this Grant.

17. DEBARMENT AND SUSPENSION

The Grantee certifies that neither it nor its principals is presently excluded or disqualified from participation in this transaction by any Federal department or agency.

18. TERRORIST FINANCING

The Grantee will not engage in transactions with, or provide resources or support to individuals and organizations associated with terrorism, including those organization and individuals identified in lists promulgated by the US Government, the United Nations and the European Union. It is the legal responsibility of the Grantee to ensure compliance with these laws. This provision must be included in all lower tier Grants issued under this Grant.

19. PROHIBITION ON ASSISTANCE TO DRUG TRAFFICKERS

FHI 360 reserves the right to terminate this Grant, to demand a refund or take measures if Grantee is found to have been convicted of a narcotic offence or engaged in drug trafficking activities.

20. PROSTITUTION AND SEX TRAFFICKING

None of the funds made available under this Grant may be used to promote or advocate the legalization or practice of prostitution or sex trafficking. Nothing in the preceding sentence shall be construed to preclude the provision to individuals of palliative care, treatment, or post-exposure pharmaceutical prophylaxis, and necessary pharmaceuticals and commodities, including test kits, condoms, and, when proven effective, microbicides.

If this Grant is for the implementation of HIV/AIDS programs, and if the Grantee is a non-US organization, the Grantee agrees that it is opposed to the practices of prostitution and sex trafficking and hereby certifies that it does not and will not promote the legalization or decriminalization or practice of prostitution or sex trafficking.

21. PROHIBITION ON ABORTION-RELATED ACTIVITIES

No funds made available under this Grant will be used to finance, support or be attributed to the following activities:

- a. Procurement or distribution of equipment intended to be used for the purpose of inducing abortions as a method of family planning;
- b. Special fees or incentives to women to coerce or motivate them to have abortions;
- c. Payments to persons to perform abortions or to solicit persons to undergo abortions;
- d. Information, education, training, or communication programs that seek to promote abortion as a method of family planning; and
- e. Lobbying for abortion.

No funds made available under this Grant will be used to pay for any biomedical research which relates, in whole or in part, to methods of, or the performance of abortions or involuntary sterilizations as a means of family planning. Epidemiologic or descriptive research to assess the incidence, extend or consequences of abortions is not precluded.

22. DELAYS

Whenever the Grantee knows, or reasonably should know, that any actual or potential condition is delaying, or threatens to delay, the timely performance of work under this Grant, the Grantee will, within five (5) days, notify the FHI 360 Grant Officer, in writing, providing all relevant information with respect to the delay.

23. NOTICES

All notices concerning business or administrative matters under this Grant will be in writing and will be directed to the FHI 360 Grant Officer named in the cover page.

All technical and program related notices and reports will be directed to the FHI 360 Technical/Program Monitor named in the cover page.

24. ENTIRE AGREEMENT

The parties acknowledge that they have read this Grant, understand it, and agree to be bound by its terms. The parties further agree that this Grant, together with all of the referenced and incorporated attachments, is the entire agreement between the parties and that it supersedes all prior agreements, written or oral, relating to the subject matter of this Grant.

If this Grant and any of its attachments are translated to a foreign language, the English version shall control.

25. LIABILITY

With regard to all aspects of this Grant, FHI 360 assumes no liability for any third-party claims or damages arising out of this Grant.

26. VALIDITY AND WAIVER

The invalidity in whole or in part of any provision of this Grant will not affect the validity of other provisions. A waiver of a breach of any provision of this Grant will not constitute a waiver of any subsequent breach of that provision or a breach of any other provision of this Grant. The failure of FHI 360 to enforce at any time or from time to time any provision of this Grant will not be construed as a waiver of the provision.

27. PERSONAL DATA PROTECTION

Grantee is responsible for ensuring its compliance with any applicable data protection laws related to its services, including but not limited to, General Data Protection Regulation (GDPR), UK-GDPR, Protection of Personal Information (POPI) Act, Nigeria Data Protection Regulation (NDPR), Brazilian General Data Protection Law (LGPD) and the Kenya Data Protection Act. To the extent Grantee processes any personal data, as defined by applicable data protection laws, on behalf of FHI 360 and in relation to which FHI 360 is the Controller, as defined by applicable data protection laws, Grantee shall: (a) act only on instructions from FHI 360 when processing personal data and keep records of all processing activities; (b) take all appropriate technical and organizational measures to protect against unauthorized or unlawful processing of, or accidental loss, destruction, or damage to, personal data; (c) process personal data in accordance with applicable data protection laws; (d) not do or permit anything to be done which might cause FHI 360 or any of its affiliates to be in violation of applicable data protection laws; (e) immediately inform FHI 360 if it believes performance of the services or compliance with any FHI 360 instruction violates or might reasonably be considered to violate any applicable data protection laws; (f) immediately notify FHI 360 of receipt of any complaint, data subject access request, notice, or communication which relates directly or indirectly to the processing of personal data under this Agreement, and provide full co-operation and assistance to FHI 360 in responding to such complaint, request, notice, or communication; (g) notify FHI 360 promptly and without undue delay upon becoming aware of any unauthorized loss, corruption, damage, destruction, alteration, disclosure, or access to, or unauthorized or unlawful processing of, any personal data ("Personal Data Breach"), or any circumstances that are likely to give rise to a Personal Data Breach, timely providing FHI 360 with sufficient information for it to meet its obligation, if any, to report a Personal Data Breach under applicable data protection laws; (h) cooperate with FHI 360 and take commercially reasonable steps as may be directed by FHI 360 to assist in the investigation, mitigation, and remediation of any Personal Data Breach; (i) cooperate as requested by FHI 360 to enable it to comply with any exercise by a data subject of rights under applicable data protection laws with respect to personal data processed by Grantee under this Agreement, or to comply with any assessment, inquiry, notice, or investigation under applicable data protection laws; (j) only permit a third party sub-processor to process personal data subject to FHI 360's prior written consent and provided that the sub-processor's contract includes terms that are substantially the same as those set out in this section; and (k) not transfer, permit a third-party processor to transfer, or allow access to personal data outside a country with restrictions on transferring data to another country without FHI 360's prior written consent, subject to any conditions FHI 360 may impose, at its sole discretion. Grantee agrees that FHI 360 may from time to time have reasonable access to Grantee's premises, systems, and records in order to audit Grantee's security measures and procedures in connection with the processing of personal data and to ensure Grantee's compliance with this section. Grantee shall indemnify, defend, and hold FHI 360 and its affiliates harmless from and against all costs, claims, damages, or expenses incurred by them due to any failure by Grantee to comply with any of its obligations under this section.

ATTACHMENT E HPTN NIH FLOW-DOWN TERMS AND CONDITIONS

PART I - CERTIFICATIONS/ASSURANCES

1. Certification Regarding Lobbying (45 CFR 75.450)

By signing this Subaward, the Subrecipient Authorized Official certifies, to the best of his/her knowledge and belief, that no Federal appropriated funds have been paid or will be paid, by or on behalf of the Subrecipient, to any person for influencing or attempting to influence an officer or employee of any agency, a Member of Congress, an officer or employee of Congress, or an employee of a Member of Congress in connection with the awarding of any Federal contract, the making of any Federal grant, the making of any Federal loan, the entering into of any cooperative agreement, and the extension, continuation, renewal, amendment, or modification of any Federal contract, grant, loan, or cooperative agreement in accordance with 45 CFR 75.450.

If any funds other than Federal appropriated funds have been paid or will be paid to any person for influencing or intending to influence an officer or employee of any agency, a Member of Congress, an officer or employee of Congress, or an employee of a Member of Congress in connection with this Federal contract, grant, loan, or cooperative agreement, the Subrecipient shall complete and submit Standard Form -LLL, "Disclosure Form to Report Lobbying," to the FHI 360.

This certification is a material representation of fact upon which reliance was placed when this transaction was made or entered into. Submission of this certification is a prerequisite for making or entering into this transaction imposed by 31 U.S.C. 1352. Any person who fails to file the required certification shall be subject to a civil penalty of not less than \$10,000 and not more than \$100,000 for each such failure.

2. Debarment, Suspension, and Other Responsibility Matters (45 CFR 75.213 and 2 CFR 180)

By signing this Subaward, the Subrecipient Authorized Official certifies, to the best of his/her knowledge and belief that neither the Subrecipient nor its principals are presently debarred, suspended, proposed for debarment, declared ineligible or voluntarily excluded from participation in this transaction by any federal department or agency, in accordance with 45 CFR 75.213 and 2 CFR 180.

3. Audit and Access to Records

Per 45 CFR 75.501- 75.521, Subrecipient certifies that it will provide notice of any adverse findings which impact this Subaward and will provide access to records as required by 45 CFR 75.364, 75.365, and 75.201 as applicable. If Subrecipient is not subject to the Single Audit Act, then Subrecipient will provide notice of the completion of any required audits and provide access to such audits upon request.

4. Program for Enhancement of Contractor Employee Protections (41 U.S.C 4712)

Subrecipient is hereby notified that they are required to: inform their employees working on any federal award that they are subject to the whistleblower rights and remedies of the pilot program; inform their employees in writing of employee whistleblower protections under 41 U.S.C §4712 in the predominant native language of the workforce; and include such requirements in any agreement made with a subcontractor or subgrantee.

5. Human Subjects (45 CFR 46)

Subrecipient certifies that it will comply with all requirements relating to human subject protections. The Subrecipient shall file and has filed will maintain all assurances or other documentation with the appropriate government agencies to the extent such assurances and documentation are required including but not limited to any requirements set forth at 45 C.F.R. Part 46 and 21 C.F.R. Part 50 (Protection of Human Subjects). Any Subrecipient enrolling/following human subjects will ensure appropriate study review and approval by Institutional Review Boards/Ethics Committees (IRBs/ECs) and other regulatory entities; including annual IRB/EC continuing reviews and submission of all required documentation in accordance to this subaward, program description and/or any applicable protocol.

The Subrecipient shall require that the language of the certifications above in this Attachment be included in the award documents for all subawards at all tiers (including subcontracts, subgrants, and contracts under grants, loans, and cooperative agreements) and that all subrecipients shall certify and disclose accordingly including disclosing any changes in the status of the above provisions for the Subrecipient and any lower tiers of the Subrecipient..

PART II – DONOR TERMS AND CONDITIONS

By signing this Subaward, Subrecipient agrees to the following:

1. To abide by the conditions on activities and restrictions on expenditure of federal funds in appropriations acts that are applicable to this Subaward to the extent those restrictions are pertinent. This includes any recent legislation noted on the Federal Awarding Agency's website: <https://grants.nih.gov/grants/policy/awardconditions.htm>
2. 2 CFR 200 and 45 CFR Part 75
3. The Federal Awarding Agency's grants policy guidance, including addenda in effect as of the beginning date of the period of performance or as amended found at: <https://grants.nih.gov/policy/nihgps/index.htm>
 - a. NOTICE: Section **4.1.37 Prohibition on Certain Telecommunications and Video Surveillance Services or Equipment** of the NIH Grants Policy Statement, updated April 2021 (<https://grants.nih.gov/grants/policy/nihgps/nihgps.pdf>) applies to this Grant.
 - b. NOTICE: Section **15.2 Administrative and Other Requirements** and **15.2.1 Written Agreement** of the NIH Grants Policy Statement, effective January 1, 2024 (<https://grants.nih.gov/grants/policy/nihgps/nihgps.pdf>) applies to this Grant.

Any foreign entity that receives a subgrant must provide access to copies of all lab notebooks, all data, and all documentation that supports the research outcomes as described in the progress report to the primary recipient no less than once per year, in alignment with the timing requirements for Research Performance Progress Report submission. Such access may be entirely electronic.

4. Research Terms and Conditions, including any Federal Awarding Agency's Specific Requirements found at: <https://www.nsf.gov/awards/managing/rte.jsp> except for the following:
 - a. No-cost extensions require the written approval of the FHI 360. Any requests for a no-cost extension shall be directed to the FHI 360 Contracting Officer not less than 30 days prior to the desired effective

date of the requested change.

- b. Any prior approvals are to be sought from FHI 360 and not the Federal Awarding Agency.
- c. Prior approval must be sought for a change in Subrecipient PI or change in Key Personnel.

5. Treatment of program income:

☐ Additive ☐ Other, Prime Recipient specify alternative from NIH Agreement ☒ Not Applicable

Special Terms and Conditions:

1. Public Access

In accordance with P.L. 110-61, compliance with the NIH Public Access Policy is now mandatory. For more information, see NOT-OD-08-033 and the Public Access website: <http://publicaccess.nih.gov/>.

2. Use of Name

Neither party shall use the other party's name, trademarks, or other logos in any publicity, advertising, or news release without the prior written approval of an authorized representative of that party. The parties agree that each party may use factual information regarding the existence and purpose of the relationship that is the subject of this Subaward for legitimate business purposes, to satisfy any reporting and funding obligations, or as required by applicable law or regulation without written permission from the other party. In any such statement, the relationship of the parties shall be accurately and appropriately described.

3. Certificates of Confidentiality

The Parties agree that this research funded in whole or in part by the National Institutes of Health ("NIH"), is subject to NIH Policy NOT-OD-17-109 (the "Policy") and therefore is deemed under the Policy to be issued a Certificate of Confidentiality ("Certificate") should the conditions outlined within apply. Accordingly, the Subrecipient is required to adhere to the Policy and protect the privacy of individuals who are subjects of such research in accordance with the Policy and subsection 301(d) of the Public Health Service Act (the "PHS Act").

4. Data Sharing and Access:

Subrecipient agrees to comply with the Federal Awarding Agency's data sharing and/or access requirements as reflected in the special terms and conditions and can be provided upon request. You can contact the FHI 360 Program/Technical Monitor for additional questions.

5. Data Rights

Subrecipient grants to FHI 360 the right to use data created in the performance of this Subaward solely for the purpose of and only to the extent required to meet FHI 360's obligations to the Federal Government under its FHI 360 Federal Award.

6. Copyrights

Subrecipient grants to FHI 360 an irrevocable, royalty-free, non-transferable, non-exclusive right and license to use, reproduce, make derivative works, display, and perform publicly any copyrights or copyrighted material (including any computer software and its documentation and/or databases) first developed and delivered under this Subaward solely for the purpose of and only to the extent required to meet FHI 360's obligations to the Federal Government under its FHI 360 Federal Award.

Subrecipient grants to FHI 360 the right to use any written progress reports and deliverables created under this Subaward solely for the purpose of and only to the extent required to meet FHI 360's obligations to the Federal Government under its Federal Award.

7. Patents Rights and Inventions

Pursuant to 37 CFR 401, title to any invention or discovery made or conceived under this Subaward shall vest in the Subrecipient to the extent the Prime award does not specify specific requirements. Should it be necessary, the Federal Government shall authorize the Prime Recipient's right to practice a Subrecipients subject invention (as well as subject data or copyrights) on behalf of the Federal Government. Subrecipient hereby grants to FHI 360 a royalty-free, non-exclusive license for research purposes to any Subrecipient invention or discovery under this Subaward.

8. Invention Reporting

In accordance with 37 CFR 401.14, Subrecipient agrees to notify both the Federal Awarding Agency via iEdison and FHI 360's Principal Investigator within 60 days after Subrecipient's inventor discloses invention(s) in writing to Subrecipient's personnel responsible for patent matters. The Subrecipient will submit a final invention report using Federal Awarding Agency specific forms to FHI 360's Principal Investigator within 60 days of the end of the Project Period to be included as part of FHI 360s final invention report to the Federal Awarding Agency.

A negative report is required ☐ Yes ☒ No ☐ Upon Request

9. Insurance

The Subrecipient assures that it carries sufficient insurance coverage to comply with the requirements of federal, state, and local laws as well as its obligations under this Subaward.

Certificate Of Completion

Envelope Id: ED234FB5E6304B3FA4E2E8B95D3CCCA6

Status: Completed

Subject: Complete with DocuSign: PO24002400 HPTN 113 SFDPH City and County SF Grant Revised 072224 PE.pdf

Source Envelope:

Document Pages: 25

Signatures: 1

Envelope Originator:

Certificate Pages: 1

Initials: 0

Christy LaTonya Smith Smith

AutoNav: Disabled

359 Blackwell Street

Envelopeld Stamping: Disabled

Suite 200

Time Zone: (UTC-08:00) Pacific Time (US & Canada)

Durham, NC 27701

cfoster@fhi360.org

IP Address: 70.40.85.155

Record Tracking

Status: Original

Holder: Christy LaTonya Smith Smith

Location: DocuSign

10/4/2024 4:14:26 PM

cfoster@fhi360.org

Signer Events**Signature****Timestamp**

Christy LaTonya Smith

cfoster@fhi360.org

Associate Director, Contract Management Services

FHI360

Security Level: Email, Account Authentication
(None)

Signed by:



550U73U44473473...

Signature Adoption: Pre-selected Style

Using IP Address: 70.40.85.155

Sent: 10/4/2024 4:16:10 PM

Viewed: 10/4/2024 4:16:18 PM

Signed: 10/4/2024 4:16:43 PM

Freeform Signing

Electronic Record and Signature Disclosure:

Not Offered via DocuSign

In Person Signer Events**Signature****Timestamp****Editor Delivery Events****Status****Timestamp****Agent Delivery Events****Status****Timestamp****Intermediary Delivery Events****Status****Timestamp****Certified Delivery Events****Status****Timestamp****Carbon Copy Events****Status****Timestamp****Witness Events****Signature****Timestamp****Notary Events****Signature****Timestamp****Envelope Summary Events****Status****Timestamps**

Envelope Sent

Hashed/Encrypted

10/4/2024 4:16:10 PM

Certified Delivered

Security Checked

10/4/2024 4:16:18 PM

Signing Complete

Security Checked

10/4/2024 4:16:43 PM

Completed

Security Checked

10/4/2024 4:16:43 PM

Payment Events**Status****Timestamps**



MODIFICATION No.01
HPTN GRANT
BETWEEN
FAMILY HEALTH INTERNATIONAL (FHI 360)
AND
CITY AND COUNTY OF SAN FRANCISCO (“GRANTEE”)


GRANT NUMBER: PO24002400


HPTN 113 Leadership
HIV PREVENTION TRIALS NETWORK (HPTN) No. UM1 AI068619
FEDERAL AWARD DATE: June 1, 2006 R&D: ☒ Yes ☐ No
CFDA NAME: Allergy and Infectious Diseases Research CFDA No: 93.855


Funding Summary	Obligated Amount	Total Estimated Award
Prior to this Modification	US \$48,915	US \$48,915
Change	US \$36,686	US \$36,686
Modified Total	US \$85,601	US \$85,601

Period of Performance	Start Date	End Date
Prior to this Modification	April 1, 2024	November 30, 2024
As Modified	UNCHANGED	NOVEMBER 30, 2025

Upon execution of this Modification, FHI 360 and the Grantee are subject to the terms and conditions of the original Grant as amended by this Modification, prior Modifications and any attachments to the Modification(s). **Grantee should return one (1) fully executed copy of this Modification to the Grant Monitor.**

Authorized by and accepted for
Family Health International by:
Signed by: 11/26/2024

Signature 059BF6E23D9845B... Date
Dominika Cadotte
Name
Contracts and Grants Officer
Title

Authorized by and accepted for
Grantee by:
Signed by: 11/14/2024 | 7:12 PM

Signature 4C9D2E27470A474... Date
Grant Colfax, MD
Name (type or print)
Director of Health
Title

DocuSigned by:

6D6CB58424584B1...
Approved as to form, David Chiu, City Attorney
By: Henry L. Lifton, Deputy City Attorney

11/14/2024 | 9:45 AM PST

SUMMARY OF MODIFICATION

The purpose of this modification is to:

- Modify the Period of Performance End Date to November 30, 2025.
- Increase the obligation by US \$36,686 for a new total obligation of US \$85,601 through November 30, 2025.
- Increase the Total Estimated Award by US \$36,686 for a new Total Estimated Award amount of US \$85,601 through November 30, 2025.
- Replace contract information for Article #10 for FHI 360 Terms and Conditions Contracts Points of Contact and FHI 360 Grant Officer.
- Revise language for Attachment D FHI 360 Terms and Conditions Section 4 Standards of Ethics and Business Conduct Introduction, 4.1 Combating Trafficking in Persons, 4.2 Safeguarding of Children in FHI 360 Programs, and 4.3 Protecting Program Participants from Sexual Exploitation and Abuse (SEA), 4.4 Violence Within the Work Environment (to add FHI 360 Policy Number), 4.5 Harassment-Free Work Environment (to add FHI 360 Policy Number, and 4.6 Dealing with Governments or Officials, Compliance with Foreign Corrupt Practices (to add FHI 360 Policy Number).
- Revise Attachment D FHI 360 Terms and Conditions Section 6 Research Integrity and Misconduct to insert language for FHI 360 Compliance office website.

MODIFICATION DETAILS

1. **Cover Page:** The period of performance end date is extended to November 30, 2025.

2. **Article 2 Type of Grant** is deleted in its entirety and revised as follows:

ARTICLE 2. TYPE OF GRANT

This is a Standard Grant that provides the following:

- (a) **TOTAL ESTIMATED AMOUNT.** The total estimated value of this Grant is US \$85,601. The Grantee agrees to use its best efforts to implement the program within the total estimated budget in *Attachment B, Budget*.
- (b) **TOTAL OBLIGATED AMOUNT.** This Grant will be incrementally funded by FHI 360. The total obligated funding for this Grant is US \$85,601 through November 30, 2025. FHI 360 will not reimburse the Grantee for expenses greater than the total obligated amount or for costs incurred outside of the period of performance of this Grant. Changes to obligated funding will be in writing as a modification to this Grant.

3. **ARTICLE #10 FHI 360 Terms and Conditions** is deleted in its entirety and replaced with the following:

ARTICLE 10. FHI 360 GRANT TERMS AND CONDITIONS

The Grant Terms and Conditions governing this Grant are set forth in **Attachment D**, FHI 360 Grant Terms and Conditions and are hereby incorporated into this Grant by reference.

FHI 360 Contracts Point of Contact

The FHI 360 Contracts Specialist Point of Contact for this award is:

Page 2 of 10



CMS Updated November 2023
HPTN 113 Leadership
SFDPH Buchbinder
Modification 01

Caroline Magoc
Contracts Specialist
Contract Management Services
FHI 360
359 Blackwell St., Ste 200
Durham, NC 27701
CMagoc@fhi360.org
919-321-3345

4. **Attachment B, Budget**, is deleted in its entirety and replaced with the revised Attachment B, Budget.
5. **Attachment C, Subrecipient Financial Report**, is deleted in its entirety and replaced with the revised Attachment C, Subrecipient Financial Report.

Attachment D, FHI 360 Grant Terms and Conditions

6. **Section 4 Standards of Ethics and Business Conduct** introductory paragraph, **4.1 Combating Trafficking in Persons**, **4.2 Safeguarding of Children in FHI 360 Programs**, and **4.3 Protecting Program Participants from Sexual Exploitation and Abuse (SEA)**, **4.4 Violence Within the Work Environment** (to add FHI 360 Policy Number), **4.5 Harassment-Free Work Environment** (to add FHI 360 Policy Number, and **4.6 Dealing with Governments or Officials**; Compliance with Foreign Corrupt Practices (to add FHI 360 Policy Number) are deleted in their entirety and replaced with the following:

4. STANDARDS OF ETHICS AND BUSINESS CONDUCT

The Grantee acknowledges and accepts FHI 360's emphasis on the importance of accountability to those who benefit from FHI 360's work, and the parties' mutual accountability to those who benefit from FHI 360's work, and the parties' mutual accountability to each other, to project collaborators, and to our sponsors. The Grantee confirms its accountability to participants in FHI 360 programs, children, any vulnerable populations and to all others whom its programs are intended to serve.

For the entirety of Section 4, Grantee personnel means any employees, consultants, volunteers, and agents of the Grantee.

4.1 Combating Trafficking in Persons: FHI 360 requires that the Grantee uphold the principles of FHI 360's Combating Trafficking in Persons policy (POL 01029) located on the FHI 360 Compliance Office website at <https://www.fhi360.org/about-us/compliance-office>. Grantee and Grantee personnel must refrain from and take steps to prevent any conduct that violates the policy. Grantee or Grantee personnel who witness conduct prohibited by the policy or who identify that Grantee personnel have engaged in such conduct should promptly report the conduct orally or in writing within 24 hours (or as soon as possible under the circumstances) to the FHI 360 Office of Compliance and Internal Audit (OCIA) by **one** of the following means: (1) via email at Compliance@fhi360.org; (2) via OCIA's Ethics and Compliance Hotline: 1-800-461-9330 in the U.S.; +1-720-514-4400 outside the U.S.; Skype: +1-800-461-9300; or Country-specific hotline numbers listed on FHI 360's reporting website; or (3) via OCIA's anonymous reporting website (<http://www.fhi360.org/anonreportregistry>). FHI 360 requires the Grantee and Grantee personnel to cooperate fully with investigations of policy violations and provide truthful information to investigators. In addition, Grantee must comply with any funder requirements incorporated into this grantee. Failure to comply



with this provision, including the failure to report or forward reports of suspected trafficking related activity, may result in immediate termination of this Grant and/or other remedial action.

4.2 Safeguarding of Children in FHI 360 Programs: Grantee must uphold the principles of the FHI 360 Safeguarding of Children policy (POL 01030) located on the FHI 360 Compliance office website at <https://www.fhi360.org/about-us/compliance-office>) to prevent abuse, neglect, and exploitation of children by the Grantee and Grantee personnel. Grant Grantee Personnel are prohibited from engaging in child abuse, exploitation, or neglect in its programs and activities, including without limitation, physical abuse; emotional ill-treatment; neglect or insufficient supervision; sexual abuse; exploitation through prostitution or production of pornographic materials; trafficking; or commercial, transaction or labor exploitation resulting in actual or potential harm to the child's health, well-being, survival, development or dignity. Grantee Personnel who witness conduct prohibited by this policy or who identify that Grantee Personnel have engaged in any such conduct must promptly report the conduct, ideally within 24 hours, or as soon as possible under the circumstances, either orally or in writing, to the FHI 360 OCIA by **one** of the following means: FHI 360 Office of Compliance and Internal Audit (OCIA) via email at Compliance@fhi360.org; FHI 360 OCIA's Ethics and Compliance Hotline: 1-800-461-9330 in the U.S.; +1-720-514-4400 outside the U.S.; Skype:+1-800-461-9300; Country-specific hotline numbers listed on FHI 360's reporting website; or FHI 360's OCIA's reporting website either with your name or anonymously (<http://www.fhi360.org/anonreportregistry>). FHI 360 requires that the Grantee cooperate fully with investigations and provide truthful information to investigators. In addition, the Grantee must comply with any funder requirements incorporated into this Grant. Failure to comply with this provision may result in termination of this Grant.

4.3 Protecting Program Participants from Sexual Exploitation and Abuse (SEA): The Grantee must uphold the principles of FHI 360's policy on Protecting Program Participants from Sexual Exploitation and Abuse (POL 01032), located on the FHI 360 Compliance office website at <https://www.fhi360.org/about-us/compliance-office>), to prevent Sexual Exploitation and Abuse by its personnel. The Grantee and Grantee Personnel are prohibited from committing any form of sexual exploitation or abuse of any adults or children who are served by FHI 360 programs or encounter Grantee Personnel engaged in activities under this Grant ("Program Participants"). Sexual exploitation means any actual or attempted abuse of Program Participants that takes advantage of their position of vulnerability or trust for sexual purpose. Sexual abuse means any actual or threatened physical intrusion of a sexual nature by force or under unequal or coercive conditions. The Grantee must take steps to develop a culture that does not tolerate SEA and to prevent, detect, and/or stop any SEA by Grantee Personnel. The Grantee or Grantee Personnel who witness conduct prohibited by FHI 360's policy on Protecting Program Participants from Sexual Exploitation and Abuse, or who identify that Grantee Personnel have engaged in any such conduct, must promptly report the conduct, ideally within 24 hours or as soon as possible under the circumstances, either orally or in writing to the FHI 360 OCIA by one of the following means: FHI 360 Office of Compliance and Internal Audit (OCIA) via email at Compliance@fhi30.org; FHI 360 OCIA's Ethics and Compliance Hotline: 1-800-461-9330 in the U.S.; +1-720-514-4400 outside the U.S.; Skype: +18--=461=9300; or Country specific hotline numbers listed on FHI 360's reporting website either with your name or anonymously (<http://www.fhi360.org/anonreportregistry>). In addition, the Grantee is required to comply fully with any funder requirements incorporated into this Grant. Failure to comply with this provision may result in termination of this Grant.

4.4 Violence Within the Work Environment: The Grantee must uphold the principles of FHI 360's Violence-Free Workplace policy (POL 03041) located on the FHI 360 Compliance office website at <https://www.fhi360.org/about-us/compliance-office>) and take steps to prohibit and prevent any form of violence or threats of violence in the work environment, by or against any Grantee Personnel while on the Grantee's premises or work locations of the Grantee, at any events sponsored by the Grantee or while engaged in the performance of employment duties for Grantee whether on or off the Grantee's premises. The Grantee's

policy must prohibit Grantee Personnel from perpetrating any form of violence or threats of violence against any staff or any Grantee partner, Grantee, or client; program participants; or anyone else with whom they interact in work-related situations.

4.5 Harassment-Free Work Environment: Grantee must uphold the principles of FHI 360's Harassment-Free Work Environment policy (POL 03029) located on the FHI 360 Compliance office website at <https://www.fhi360.org/about-us/compliance-office>) and take steps to prohibit and prevent Grantee Personnel are prohibited from engaging in any form of harassment in the workplace or work-related situations based on: race, color, ethnic or national origin, religion, age, sex, sexual orientation, gender identity, or perceived adherence to socially defined norms of masculinity and femininity, medical conditions, pregnancy, childbirth, and breastfeeding, nationality or citizenship, physical or mental disability, genetic information or characteristics (or those of a family member), protected U.S. military or U.S. veteran status, status as a victim of domestic violence, sexual assault or stalking, and/or any other class, status, or characteristic protected by local law. The Grantee must strictly prohibit Grantee Personnel from harassing any Grantee Personnel, employees of any Grantee partner, Grantee, or client; program participants; or anyone else with whom the Grantee Personnel interact in work-related situations.

4.6 Dealing with Governments or Officials; Compliance with Foreign Corrupt Practices Act: The Grantee acknowledges that FHI 360 corporate policy (POL 01015) located on the FHI 360 Compliance office website at <https://www.fhi360.org/about-us/compliance-office> requires that FHI 360's activities be conducted within the letter and spirit of the law. The Grantee, including any of its affiliates and their respective employees, agents officers, or other members of its management will not make any payment, either directly or indirectly, of money or other assets to government or political party officials, candidates for public office, or representatives of other businesses or persons acting on behalf of any of the foregoing (referred to collectively as "officials") where such payment would constitute a violation of any law. In addition, regardless of legality, the Grantee will make no payment either directly or indirectly to officials if such payment is for the purpose of influencing decisions or actions with respect to the subject matter of this Grant or any other aspect of FHI 360's operations.

7. Section 6 Research Integrity and Misconduct is deleted in its entirety and replaced with the following:

6. RESEARCH INTEGRITY AND MISCONDUCT

FHI 360 requires that research is conducted with the highest standards of integrity and ethical behavior regardless of the funding source or type of research. FHI 360 employees and related personnel have a personal responsibility for implementing FHI 360's Research Integrity and Misconduct policy located on the FHI 360 Compliance office website at <https://www.fhi360.org/about-us/compliance-office> . The policy requires anyone having reason to believe that a person has engaged in research misconduct to report his/her concern of possible research misconduct to the FHI 360 Research Integrity Officer (RIO). When research is supported by the Public Health Service (PHS), National Science Foundation (NSF) and other Federal Agencies FHI 360 complies with special reporting requirements found in PHS Policies on Research Misconduct – 42 CFR Part 93 and NSF regulations at 45 CFR 689. FHI 360 subawardees and subcontractors are responsible for handling research misconduct in compliance with applicable federal regulations, local laws and agreement terms and conditions. In addition, FHI 360 subawardees and subcontractors are expected to inquire into, and if necessary, investigate and resolve promptly and fairly all instances of alleged research misconduct related to the subaward or subcontract, such review to comply with applicable federal regulations, local laws, and agreement terms and conditions. For determinations of research misconduct while engaged in FHI 360 research activities, subawardees and subcontractors are required to provide a report to the RIO that details the facts and analysis that supports the conclusion,

identifies the type of research misconduct, describes any mitigating steps and/or administrative and disciplinary actions taken, list all individuals and/or organizations notified, includes any supporting documentation of the misconduct, and provides any other relevant information pertinent to the investigation. At the discretion of the RIO, the RIO may take custody of all research records and evidence to meet any applicable legal and/or regulatory requirements.

All other terms and conditions remain unchanged and in effect.

ATTACHMENTS

- B. Budget
- C. Subrecipient Financial Report



ATTACHMENT B BUDGET



Subawardee:	<u>City and County of San Francisco</u>	Start Date:	<u>4/1/2024</u>
PO#	<u>PO24002400</u>	End Date:	<u>11/30/2025</u>
Subaward title:	<u>HPTN 113 Leadership (Buchbinder)</u>		

	Previous Funding Period Obligation	Current Funding Period Obligation	Total Obligation	Total Life of Project
	Apr 1 2024 - Nov 30 2024	Dec 1 2024 - Nov 30 2024	Apr 1 2024 - Nov 30 2025	Apr 1 2024 - Nov 30 2025
	Amount	Amount	Amount	Amount
	USD	USD	USD	USD
1. SALARIES	29,587	22,190	51,777	51,777
2. FRINGE BENEFITS	10,356	7,767	18,123	18,123
3. CONSULTANTS	-		-	-
4. EQUIPMENT	-		-	-
5. TRAVEL/TRANSPORTATION	-		-	-
6. SUBAWARDS	-		-	-
7. OTHER DIRECT COSTS	-		-	-
8. INDIRECT COST/G&A	8,972	6,729	15,701	15,701
TOTAL PROJECT COSTS	48,915	36,686	85,601	85,601



Reporting Cycle - Monthly



SUBAWARDEE FINANCIAL REPORT (SFR)

The Subawardee Financial Report must be submitted to FHI 360 in accordance with the terms and conditions of the Grant. All amounts must be entered in the same currency and in accordance with the terms and conditions of the Grant.

Note: if using the electronic version of this report, input should be entered into the shaded areas. Other areas are calculations.

HEADER SECTION

Submit Reports to:	Enter the name and FHI 360 office & city where the report is submitted.
ID/FCO No.:	Enter the ID/FCO Number shown in the Grant document.
Reporting Period:	Enter the period / dates covered by the report (month and year).
Subaward Start Date:	Enter the start date of the Grant according to the Grant document.
Today's Date:	Enter the day in which the report is completed.
Subaward End Date:	Enter the end date of the project based on the Grant or latest amendment / modification.
Currency:	Enter the type of currency used to report all financial information. This currency should be in accordance with the terms and conditions of the Grant.
Subawardee Name:	Enter the Grantee name as shown in the Grant document.
Project Title:	Enter the project name as shown in the Grant document.
Reporting Cycle:	Indicate the reporting cycle as indicated in the Grant document.

I. BUDGET ANALYSIS

Current Obligations:	Enter the budget amount for each line item reflected on the Summary Budget in the latest Grant document. The budget amount for each line item must be in the currency indicated in the Grant document.
Total Expenses Previously Reported:	Enter the <i>Total Expended to Date</i> amounts in each line item from the previous report.
Expended This Reporting Period:	Enter the amount spent during the period covered by this report into the respective line items.
Total Expended to Date:	Enter the sum of <i>Total Expenses Previously Reported</i> and <i>Expended This Reporting Period</i> .
Obligated Funds Remaining:	Enter the <i>Current Obligation</i> less <i>Total Expended to Date</i> .
Total USD:	Enter the total current obligation in US dollars reflected on the Summary Budget in the latest Grant document.
Subaward Exchange Rate:	Enter the exchange rate used to convert US dollars to the currency used for reporting, if applicable. The rate is for INFORMATIONAL PURPOSES ONLY to show the conversion between the two currencies if applicable. This rate should match the rate on the Summary Budget of the latest Grant document (it is suggested that it be linked to the Summary Budget page if possible).
***Attachments Required	For budget categories marked with an asterisk (*), attach an itemized list of expenditures for the reporting period: Example:



1. **Consultants and professional fees** requires a list of payments made during the period indicating the name of the payee, daily rate, total paid, and a brief description of the services performed.
2. **Procurement** requires a description of the equipment, vendor name, amount paid, and the date of purchase.
3. **Other Direct Costs** requires a schedule of all direct costs associated with project activities that are not allocated to the categories above.
4. **Other** requires a description of other allowable costs in accordance with the Grant document. The type of expense must be specified.

II. SUMMARY OF FUNDS

Funds Previously Received:	Enter the amount received as of the beginning of the period. This amount should be equal to the Total Funds Received from FHI 360 line on the previous report.
Funds Received this Period:	Enter the amount of all wires or checks received this period. Upon review, FHI 360 Finance will enter the US dollar equivalent amount based on General Ledger information.
Wire/Check No.:	Enter the wire or check number from funds received.
Total Funds Received from FHI 360:	Enter the sum of <i>Funds Previously Received</i> line and the <i>Funds Received this Period</i> line.
Total Amount Expended	Enter the total amount in the <i>Total Expended to Date</i> column above.
Balance on Hand	Enter the differences between the Total Funds Received from FHI 360 and the Total Amount Expended lines. This should equal the total cash on hand at the end of the period. All unspent funds are to be returned to FHI 360 within the period stated in the Grant.
***Attachments Required	A copy of the bank statement and bank reconciliation must be submitted to support the amount stated as the balance on hand.
Interest Earned	Record interest earned if the bank account earns interest. Grantee is allowed to keep \$250 annually to cover administrative expenses
USD Current Obligated Amount	Enter the total current obligation amount in US dollars shown in the Grant or current amendment. This should be the same as the <i>Total USD</i> amount above.
USD Obligation Remaining:	Enter the US Current Obligated Amount less Total Funds Received from FHI 360 (US
Total USD Obligation Less USD Sent as of this Rpt:	dollars).

Note: FHI 360 Finance will enter amounts in US dollars based on FHI 360's General Ledger. This information will be communicated to the Grantee periodically to compare against the US dollar amount in the Grant as the US dollar amount prevails in a majority of the Grants. The current bank rate should be used when converting the balance on hand to estimated US dollar equivalent.

III. CERTIFICATION AND APPROVALS

Certification and approval:	This report must be certified and signed by the Grantee's Authorized Official and approved by FHI 360's Technical/Program Monitor.
Review:	In addition to being approved by FHI 360's Technical/Program Monitor, this report must also be reviewed by the FHI 360 Finance department.



Certificate Of Completion

Envelope Id: E8159D7C2E414F019EA1250FDA2B4F7B		Status: Completed
Subject: Complete with Docusign: PO24002400 HPTN 113 Leadership Buchbinder SFDPH Mod 1_PE.pdf		
Source Envelope:		
Document Pages: 10	Signatures: 1	Envelope Originator:
Certificate Pages: 1	Initials: 0	Dominika Cadotte
AutoNav: Disabled		359 Blackwell Street
Envelopeld Stamping: Disabled		Suite 200
Time Zone: (UTC-08:00) Pacific Time (US & Canada)		Durham, NC 27701
		dcadotte@fhi360.org
		IP Address: 155.190.22.3

Record Tracking


Status: Original	Holder: Dominika Cadotte	Location: DocuSign
11/26/2024 4:25:32 AM	dcadotte@fhi360.org	

Signer Events

Dominika Cadotte
dcadotte@fhi360.org
Contracts and Grants Officer
FHI 360
Security Level: Email, Account Authentication (None)

Signature

Signed by:



DD9BF6E23D9845B...

Signature Adoption: Pre-selected Style
Using IP Address: 155.190.22.3

Timestamp

Sent: 11/26/2024 4:25:40 AM
Viewed: 11/26/2024 4:25:46 AM
Signed: 11/26/2024 4:26:09 AM
Freeform Signing

Electronic Record and Signature Disclosure:
Not Offered via DocuSign

In Person Signer Events

Signature

Timestamp

Editor Delivery Events

Status

Timestamp

Agent Delivery Events

Status

Timestamp

Intermediary Delivery Events

Status

Timestamp

Certified Delivery Events

Status

Timestamp

Carbon Copy Events

Status

Timestamp

Witness Events

Signature

Timestamp

Notary Events

Signature

Timestamp

Envelope Summary Events

Status

Timestamps

Envelope Sent	Hashed/Encrypted	11/26/2024 4:25:40 AM
Certified Delivered	Security Checked	11/26/2024 4:25:46 AM
Signing Complete	Security Checked	11/26/2024 4:26:09 AM
Completed	Security Checked	11/26/2024 4:26:09 AM

Payment Events

Status

Timestamps



MODIFICATION No.02
HPTN GRANT
BETWEEN
FAMILY HEALTH INTERNATIONAL (FHI 360)
AND
CITY AND COUNTY OF SAN FRANCISCO (“GRANTEE”)

GRANT NUMBER: PO24002400

HPTN 113 Leadership
HIV PREVENTION TRIALS NETWORK (HPTN) No. UM1 AI068619
FEDERAL AWARD DATE: June 1, 2006 R&D: ☒ Yes ☐ No
CFDA NAME: Allergy and Infectious Diseases Research CFDA No: 93.855

Funding Summary	Obligated Amount	Total Estimated Award
Prior to this Modification	US \$85,601	US \$85,601
Change	US \$23,367	US \$23,367
Modified Total	US \$108,968	US \$108,968

Period of Performance	Start Date	End Date
Prior to this Modification	April 1, 2024	November 30, 2025
As Modified	UNCHANGED	UNCHANGED

Upon execution of this Modification, FHI 360 and the Grantee are subject to the terms and conditions of the original Grant as amended by this Modification, prior Modifications and any attachments to the Modification(s). **Grantee should return one (1) fully executed copy of this Modification to the Grant Monitor.**

Authorized by and accepted for
Family Health International by:

Signed by:

Dominika Cadotte

DD9BF6E23D9845B...

4/17/2025

Signature

Date

Dominika Cadotte

Name

Contracts and Grants Officer

Title

Authorized by and accepted for
Grantee by:

Signed by:

Susan Philip

4C9D2E27476A474...

04/17/2025 | 11:26 AM

Signature

Date

Daniel Tsai

Name (type or print)

Director of Health

Title

Approved as to form, David Chiu, City Attorney
By:

Signed by:

Bess Htisam Hanish

D0523AF4F16D451...

SUMMARY OF MODIFICATION

The purpose of this modification is to:

- Increase the obligation by US \$23,367 for a new total obligation of US \$108,968 through November 30, 2025.
- Increase the Total Estimated Award by US \$23,367 for a new Total Estimated Award amount of US \$108,968 through November 30, 2025.

MODIFICATION DETAILS

1. **Article 2 Type of Grant** is deleted in its entirety and revised as follows:

ARTICLE 2. TYPE OF GRANT

This is a Standard Grant that provides the following:

- (a) **TOTAL ESTIMATED AMOUNT.** The total estimated value of this Grant is US \$108,968. The Grantee agrees to use its best efforts to implement the program within the total estimated budget in *Attachment B, Budget*.
 - (b) **TOTAL OBLIGATED AMOUNT.** This Grant will be incrementally funded by FHI 360. The total obligated funding for this Grant is US \$108,968 through November 30, 2025. FHI 360 will not reimburse the Grantee for expenses greater than the total obligated amount or for costs incurred outside of the period of performance of this Grant. Changes to obligated funding will be in writing as a modification to this Grant.
2. **Attachment B, Budget**, is deleted in its entirety and replaced with the revised Attachment B, Budget.
 3. **Attachment C, Subrecipient Financial Report**, is deleted in its entirety and replaced with the revised Attachment C, Subrecipient Financial Report.

All other terms and conditions remain unchanged and in effect.

ATTACHMENTS

- B. Budget
- C. Subrecipient Financial Report



ATTACHMENT B
BUDGET



Subawardee:	City and County of San Francisco	Start Date:	4/1/2024
PO#	PO24002400	End Date:	11/30/2025
Subaward title:	HPTN 113 Leadership (Buchbinder)		

	Previous Funding Period Obligation	Current Funding Period Obligation	Additional Funding Current Period	Deobligation	Total Obligation	Total Life of Project
	Apr 1 2024 - Nov 30 2024	Dec 1 2024 - Nov 30 2025	Dec 1 2024 - Nov 30 2025	Apr 1 2024 - Nov 30 2025	Apr 1 2024 - Nov 30 2025	Apr 1 2024 - Nov 30 2025
	Amount	Amount	Amount	Amount	Amount	Amount
	USD	USD	USD	USD	USD	USD
1. SALARIES	29,587	22,190	22,190	(5,434)	68,533	68,533
2. FRINGE BENEFITS	10,356	7,767	7,101	(4,776)	20,448	20,448
3. CONSULTANTS	-				-	-
4. EQUIPMENT	-				-	-
5. TRAVEL/TRANSPORTATION	-				-	-
6. SUBAWARDS	-				-	-
7. OTHER DIRECT COSTS	-				-	-
8. INDIRECT COST/G&A	8,972	6,729	6,579	(2,293)	19,987	19,987
TOTAL PROJECT COSTS	48,915	36,686	35,870	(12,503)	108,968	108,968



ATTACHMENT C



Subawardee Financial Report

This report must be submitted to FHI 360 in accordance with the subaward's financial reporting requirements and indicated due dates.

Submit report to: HPTNInvoice@FHI360.org

Reporting Cycle - Monthly

PO No. PO24002400 Reporting Period
 Subaward Start Date 4/1/2024 Today's Date [date]
 Subaward End Date 11/30/2025 Currency: USD
 Subawardee Name City and County of San Francisco
 Subaward Title: HPTN 113 Leadership (Buchbinder)

I. Budget Analysis	Current Obligation 12/01/2024 - 11/30/2025	Total Expenses Previously Reported	Expended This Reporting Period	Total Expended to Date	Obligated Funds Remaining
<i>Amendment #</i>					
Salaries	44,380				44,380
Fringe Benefits (if applicable)	14,868				14,868
Consultants / Professional Fees					
Equipment					
Travel, Transportation, and Per Diem					
Contractual/Subawards					
Other Direct Costs					
Indirect Costs / G&A	13,308				13,308
Other (Specify) =>					
TOTAL	72,556				72,556

Please note that all required supporting documentation per the Terms & Conditions of the subaward must be attached to this form.

II. Summary of Funds

	Amount
Funds Previously Received	
Funds Received this Period	
Total Funds Received from FHI 360	
Total Amount Expended	
Balance on Hand	
Total Interest Earned	

III. Certification and Approval:

I certify that to the best of my knowledge and belief, this Financial Report is a correct, complete and accurate statement, that my organization is properly entitled to payment, and that all amounts requested are for appropriate purposes in strict accordance with the terms and conditions of the subaward.

Subawardee Authorized Official:

Typed name, Title Signature Date

FHI 360 Review and Approval:

FHI 360 Subaward Monitor :

Typed name, Title Signature Date

FHI 360 Finance:

Typed name, Title Signature Date



SUBAWARDEE FINANCIAL REPORT (SFR)

The Subawardee Financial Report must be submitted to FHI 360 in accordance with the terms and conditions of the Grant. All amounts must be entered in the same currency and in accordance with the terms and conditions of the Grant.

Note: if using the electronic version of this report, input should be entered into the shaded areas. Other areas are calculations.

HEADER SECTION

Submit Reports to:	Enter the name and FHI 360 office & city where the report is submitted.
ID/FCO No.:	Enter the ID/FCO Number shown in the Grant document.
Reporting Period:	Enter the period / dates covered by the report (month and year).
Subaward Start Date:	Enter the start date of the Grant according to the Grant document.
Today's Date:	Enter the day in which the report is completed.
Subaward End Date:	Enter the end date of the project based on the Grant or latest amendment / modification.
Currency:	Enter the type of currency used to report all financial information. This currency should be in accordance with the terms and conditions of the Grant.
Subawardee Name:	Enter the Grantee name as shown in the Grant document.
Project Title:	Enter the project name as shown in the Grant document.
Reporting Cycle:	Indicate the reporting cycle as indicated in the Grant document.

I. BUDGET ANALYSIS

Current Obligations:	Enter the budget amount for each line item reflected on the Summary Budget in the latest Grant document. The budget amount for each line item must be in the currency indicated in the Grant document.
Total Expenses Previously Reported:	Enter the <i>Total Expended to Date</i> amounts in each line item from the previous report.
Expended This Reporting Period:	Enter the amount spent during the period covered by this report into the respective line items.
Total Expended to Date:	Enter the sum of <i>Total Expenses Previously Reported</i> and <i>Expended This Reporting Period</i> .
Obligated Funds Remaining:	Enter the <i>Current Obligation</i> less <i>Total Expended to Date</i> .
Total USD:	Enter the total current obligation in US dollars reflected on the Summary Budget in the latest Grant document.
Subaward Exchange Rate:	Enter the exchange rate used to convert US dollars to the currency used for reporting, if applicable. The rate is for INFORMATIONAL PURPOSES ONLY to show the conversion between the two currencies if applicable. This rate should match the rate on the Summary Budget of the latest Grant document (it is suggested that it be linked to the Summary Budget page if possible).
***Attachments Required	For budget categories marked with an asterisk (*), attach an itemized list of expenditures for the reporting period: Example:



1. **Consultants and professional fees** requires a list of payments made during the period indicating the name of the payee, daily rate, total paid, and a brief description of the services performed.
2. **Procurement** requires a description of the equipment, vendor name, amount paid, and the date of purchase.
3. **Other Direct Costs** requires a schedule of all direct costs associated with project activities that are not allocated to the categories above.
4. **Other** requires a description of other allowable costs in accordance with the Grant document. The type of expense must be specified.

II. SUMMARY OF FUNDS

Funds Previously Received:	Enter the amount received as of the beginning of the period. This amount should be equal to the Total Funds Received from FHI 360 line on the previous report.
Funds Received this Period:	Enter the amount of all wires or checks received this period. Upon review, FHI 360 Finance will enter the US dollar equivalent amount based on General Ledger information.
Wire/Check No.:	Enter the wire or check number from funds received.
Total Funds Received from FHI 360:	Enter the sum of <i>Funds Previously Received</i> line and the <i>Funds Received this Period</i> line.
Total Amount Expended	Enter the total amount in the <i>Total Expended to Date</i> column above.
Balance on Hand	Enter the differences between the Total Funds Received from FHI 360 and the Total Amount Expended lines. This should equal the total cash on hand at the end of the period. All unspent funds are to be returned to FHI 360 within the period stated in the Grant.
***Attachments Required	A copy of the bank statement and bank reconciliation must be submitted to support the amount stated as the balance on hand.
Interest Earned	Record interest earned if the bank account earns interest. Grantee is allowed to keep \$250 annually to cover administrative expenses
USD Current Obligated Amount	Enter the total current obligation amount in US dollars shown in the Grant or current amendment. This should be the same as the <i>Total USD</i> amount above.
USD Obligation Remaining:	Enter the US Current Obligated Amount less Total Funds Received from FHI 360 (US
Total USD Obligation Less USD Sent as of this Rpt:	dollars).

Note: FHI 360 Finance will enter amounts in US dollars based on FHI 360's General Ledger. This information will be communicated to the Grantee periodically to compare against the US dollar amount in the Grant as the US dollar amount prevails in a majority of the Grants. The current bank rate should be used when converting the balance on hand to estimated US dollar equivalent.

III. CERTIFICATION AND APPROVALS

Certification and approval:	This report must be certified and signed by the Grantee's Authorized Official and approved by FHI 360's Technical/Program Monitor.
Review:	In addition to being approved by FHI 360's Technical/Program Monitor, this report must also be reviewed by the FHI 360 Finance department.



Certificate Of Completion

Envelope Id: 2D02D99C-8C3C-4C20-ABB6-0DE72DA79EB5

Status: Completed

Subject: Complete with Docusign: For Signature HPTN 113 PO24002400 SFDPH City and County SF - Modificati...

Source Envelope:

Document Pages: 6

Signatures: 1

Envelope Originator:

Certificate Pages: 1

Initials: 0

Dominika Cadotte

AutoNav: Disabled

359 Blackwell Street

Envelopeld Stamping: Disabled

Suite 200

Time Zone: (UTC-08:00) Pacific Time (US & Canada)

Durham, NC 27701

dcadotte@fhi360.org

IP Address: 155.190.61.27

Record Tracking

Status: Original

Holder: Dominika Cadotte

Location: DocuSign

4/17/2025 12:57:39 PM

dcadotte@fhi360.org

Signer Events

Signature

Timestamp

Dominika Cadotte

dcadotte@fhi360.org

Contracts and Grants Officer

FHI 360

Security Level: Email, Account Authentication
(None)

Signed by:
Dominika Cadotte
DD9BF6E23D9845B...

Signature Adoption: Pre-selected Style

Using IP Address: 155.190.18.44

Sent: 4/17/2025 12:57:49 PM

Viewed: 4/17/2025 12:57:53 PM

Signed: 4/17/2025 12:58:21 PM

Freeform Signing

Electronic Record and Signature Disclosure:

Not Offered via Docusign

In Person Signer Events

Signature

Timestamp

Editor Delivery Events

Status

Timestamp

Agent Delivery Events

Status

Timestamp

Intermediary Delivery Events

Status

Timestamp

Certified Delivery Events

Status

Timestamp

Carbon Copy Events

Status

Timestamp

Witness Events

Signature

Timestamp

Notary Events

Signature

Timestamp

Envelope Summary Events

Status

Timestamps

Envelope Sent

Hashed/Encrypted

4/17/2025 12:57:49 PM

Certified Delivered

Security Checked

4/17/2025 12:57:53 PM

Signing Complete

Security Checked

4/17/2025 12:58:21 PM

Completed

Security Checked

4/17/2025 12:58:21 PM

Payment Events

Status

Timestamps



City and County of San Francisco
Daniel Lurie
Mayor

San Francisco Department of Public Health

Daniel Tsai
Director of Health

Memorandum

To: Honorable Members of the Board of Supervisors

From: San Francisco Department of Public Health

Date: Thursday, July 17, 2025

RE: **Retroactivity re: Files 250725 and 250743**

These Resolutions seek authorization for the Department of Public Health (DPH) to retroactively accept and expend two grant increases in the amounts of \$105,832 and \$108,968, respectively, from the National Institutes of Health (NIH) through the Fred Hutchinson Cancer Center and Family Health International for HIV research and prevention.

File 250725: Accept and Expend Grant - Retroactive - National Institutes of Health - Fred Hutchinson Cancer Center - Statistical Methods for Advancing HIV Prevention - \$105,832 – The initial project period for this grant began on March 1, 2023. DPH has since received several increases for this grant. DPH received notice of the most recent grant increase on May 12, 2025, for a project start date of March 1, 2025. The project start date was predetermined by the grantor. Upon receiving the notice of grant increase, DPH brought the item to the Controller's Office for review on May 30, 2025. The Controller's Office reviewed and forwarded the packet to the Mayor's Office on June 23, 2025, for introduction on July 1, 2025.

File 250743: Accept and Expend Grant - Retroactive - National Institutes of Health - Family Health International - HIV Prevention Trials Network - \$108,968 - The initial project period for this grant began on April 1, 2024. DPH has since received several increases for this grant. DPH received notice of the most recent grant increase on April 17, 2025, for a project start date of March 1, 2025. The project start date was predetermined by the grantor. Upon receiving the notice of grant increase, DPH brought the item to the Controller's Office for review on June 3, 2025. The Controller's Office reviewed and forwarded the packet to the Mayor's Office on June 30, 2025, for introduction on July 8, 2025.

We respectfully request retroactive authorization for these items. Please contact Christina Chiong, SFDPH Accept & Expend Unit Manager, at christina.chiong@sfdph.org for any questions about this request for retroactive authorization.



Daniel Lurie
Mayor

TO: Angela Calvillo, Clerk of the Board of Supervisors

FROM: Daniel Tsai
Director of Health

DATE: 7/9/2025

SUBJECT: Grant Accept and Expend

GRANT TITLE: HIV Prevention Trials Network (HPTN) - \$108,968

Attached please find the original and 1 copy of each of the following:

- ☒ Proposed grant resolution, original signed by Department
- ☒ Grant information form, including disability checklist
- ☒ Budget and Budget Justification
- ☐ Grant application: Not Applicable. No application submitted.
- ☒ Agreement / Award Letter
- ☐ Other (Explain):

Special Timeline Requirements:

Departmental representative to receive a copy of the adopted resolution:

Name: Gregory Wong (greg.wong@sfdph.org) Phone: 554-2521

Interoffice Mail Address: Dept. of Public Health, 101 Grove St # 108

Certified copy required Yes ☐

No ☒

OFFICE OF THE MAYOR
SAN FRANCISCO



DANIEL LURIE
MAYOR

TO: Angela Calvillo, Clerk of the Board of Supervisors
FROM: Adam Thongsavat, Liaison to the Board of Supervisors
RE: Accept and Expend Grant - Retroactive - National Institutes of Health - Family Health
International - HIV Prevention Trials Network (HPTN) - \$108,968
DATE: July 8, 2025

Resolution retroactively authorizing the Department of Public Health to accept and expend a grant from the National Institutes of Health through the Family Health International for participation in a program, entitled "HIV Prevention Trials Network (HPTN)," in the amount of \$108,968 for the period of April 1, 2024, through November 30, 2025.

Should you have any questions, please contact Adam Thongsavat at adam.thongsavat@sfgov.org